<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="publisher-id">nar</journal-id>
    <journal-title-group>
      <journal-title>Nucleic Acids Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0305-1048</issn>
    <issn pub-type="epub">1362-4962</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9825476</article-id>
    <article-id pub-id-type="pmid">36395823</article-id>
    <article-id pub-id-type="doi">10.1093/nar/gkac1013</article-id>
    <article-id pub-id-type="publisher-id">gkac1013</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00010</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Database Issue</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>GPCRdb in 2023: state-specific structure models using AlphaFold2 and new ligand resources</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Pándy-Szekeres</surname>
          <given-names>Gáspár</given-names>
        </name>
        <aff><institution>Department of Drug Design and Pharmacology, University of Copenhagen</institution>, Universitetsparken 2, 2100 Copenhagen, <country country="DK">Denmark</country></aff>
        <aff><institution>Medicinal Chemistry Research Group, Research Center for Natural Sciences</institution>, Budapest H-1117, <country country="HU">Hungary</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Caroli</surname>
          <given-names>Jimmy</given-names>
        </name>
        <aff><institution>Department of Drug Design and Pharmacology, University of Copenhagen</institution>, Universitetsparken 2, 2100 Copenhagen, <country country="DK">Denmark</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Mamyrbekov</surname>
          <given-names>Alibek</given-names>
        </name>
        <aff><institution>Department of Drug Design and Pharmacology, University of Copenhagen</institution>, Universitetsparken 2, 2100 Copenhagen, <country country="DK">Denmark</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Kermani</surname>
          <given-names>Ali A</given-names>
        </name>
        <aff><institution>Department of Structural Biology, St. Jude Children's Research Hospital</institution>, Memphis, TN 38105, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Keserű</surname>
          <given-names>György M</given-names>
        </name>
        <aff><institution>Medicinal Chemistry Research Group, Research Center for Natural Sciences</institution>, Budapest H-1117, <country country="HU">Hungary</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5514-6021</contrib-id>
        <name>
          <surname>Kooistra</surname>
          <given-names>Albert J</given-names>
        </name>
        <!--albert.kooistra@sund.ku.dk-->
        <aff><institution>Department of Drug Design and Pharmacology, University of Copenhagen</institution>, Universitetsparken 2, 2100 Copenhagen, <country country="DK">Denmark</country></aff>
        <xref rid="FN2" ref-type="author-notes"/>
        <xref rid="COR2" ref-type="corresp"/>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4299-7561</contrib-id>
        <name>
          <surname>Gloriam</surname>
          <given-names>David E</given-names>
        </name>
        <!--david.gloriam@sund.ku.dk-->
        <aff><institution>Department of Drug Design and Pharmacology, University of Copenhagen</institution>, Universitetsparken 2, 2100 Copenhagen, <country country="DK">Denmark</country></aff>
        <xref rid="FN2" ref-type="author-notes"/>
        <xref rid="COR1" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Tel: +45 93 56 54 49; Fax: +45 35 33 60 41; Email: <email>david.gloriam@sund.ku.dk</email></corresp>
      <corresp id="COR2">Correspondence may also be addressed to Albert J. Kooistra. Tel: +45 35 32 83 05; Email: <email>albert.kooistra@sund.ku.dk</email></corresp>
      <fn id="FN1">
        <p>The authors wish it to be known that, in their opinion, the first two authors should be regarded as Joint First Authors.</p>
      </fn>
      <fn id="FN2">
        <p>The authors wish it to be known that, in their opinion, the last two authors should be regarded as Joint Last Authors.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="collection">
      <day>06</day>
      <month>1</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2022-11-18">
      <day>18</day>
      <month>11</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>18</day>
      <month>11</month>
      <year>2022</year>
    </pub-date>
    <volume>51</volume>
    <issue>D1</issue>
    <fpage>D395</fpage>
    <lpage>D402</lpage>
    <history>
      <date date-type="accepted">
        <day>09</day>
        <month>11</month>
        <year>2022</year>
      </date>
      <date date-type="rev-recd">
        <day>15</day>
        <month>10</month>
        <year>2022</year>
      </date>
      <date date-type="received">
        <day>15</day>
        <month>9</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2022. Published by Oxford University Press on behalf of Nucleic Acids Research.</copyright-statement>
      <copyright-year>2023</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="gkac1013.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>G protein-coupled receptors (GPCRs) are physiologically abundant signaling hubs routing hundreds of extracellular signal substances and drugs into intracellular pathways. The GPCR database, GPCRdb supports &gt;5000 interdisciplinary researchers every month with reference data, analysis, visualization, experiment design and dissemination. Here, we present our fifth major GPCRdb release setting out with an overview of the many resources for receptor sequences, structures, and ligands. This includes recently published additions of class D generic residue numbers, a comparative structure analysis tool to identify functional determinants, trees clustering GPCR structures by 3D conformation, and mutations stabilizing inactive/active states. We provide new state-specific structure models of all human non-olfactory GPCRs built using AlphaFold2-MultiState. We also provide a new resource of endogenous ligands along with a larger number of surrogate ligands with bioactivity, vendor, and physiochemical descriptor data. The one-stop-shop ligand resources integrate ligands/data from the ChEMBL, Guide to Pharmacology, PDSP Ki and PubChem database. The GPCRdb is available at <ext-link xlink:href="https://gpcrdb.org" ext-link-type="uri">https://gpcrdb.org</ext-link>.</p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Lundbeck Foundation</institution>
            <institution-id institution-id-type="DOI">10.13039/501100003554</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>R313-2019-526</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Novo Nordisk Foundation</institution>
            <institution-id institution-id-type="DOI">10.13039/501100009708</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>NNF18OC0031226</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Hungarian Academy of Sciences</institution>
            <institution-id institution-id-type="DOI">10.13039/501100003825</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>NAP3.0</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="8"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>INTRODUCTION</title>
    <p>G protein-coupled receptors (GPCRs) account for 799 (<xref rid="B1" ref-type="bibr">1</xref>) out of 20 383 (<xref rid="B2" ref-type="bibr">2</xref>) (4%) human genes and transduce the responses of two-thirds (342/515) of signaling substances (<xref rid="B3" ref-type="bibr">3</xref>). Their predominant role in physiology is mirrored in medicine, as 34% of marketed drugs target GPCRs (<xref rid="B4" ref-type="bibr">4</xref>). The GPCR database, GPCRdb serves ∼5000 researchers every month with reference data, analysis, visualization, experiment design and data deposition. GPCRdb is open access and open source, and compliant with the FAIR principles (<xref rid="B5" ref-type="bibr">5</xref>). In 2022, what was previously a G protein section of GPCRdb grew into a dedicated database, GproteinDb adding, e.g. a coupling atlas integrating major datasets (<xref rid="B6" ref-type="bibr">6</xref>), structure complexes with GPCRs, and interface interactions (<xref rid="B7" ref-type="bibr">7</xref>). Also ArrestinDb (<xref rid="B8" ref-type="bibr">8</xref>) and Biased Signaling Atlas (<xref rid="B9" ref-type="bibr">9</xref>) have been much expanded and are brought forward as separate resources covering complementary aspects of signal transduction while serving dedicated research communities and use cases.</p>
    <p>GPCRdb has long provided state-of-the-art homology models from a unique multi-template pipeline. However, current advances call for a transition towards machine-learning based models taking advantage of recent breakthroughs. AlphaFold2 was, together with RoseTTA-fold, awarded the method and breakthrough of the year by <italic toggle="yes">Nature</italic> (<xref rid="B10" ref-type="bibr">10</xref>) and <italic toggle="yes">Science</italic> (<xref rid="B11" ref-type="bibr">11</xref>), respectively. While pre-generated AlphaFold2 models can be downloaded from the European Bioinformatics Institute (<xref rid="B12" ref-type="bibr">12</xref>), they have limitations of both general and GPCR-specific scope. Furthermore, AlphaFold models are provided for only one structural/functional state of each protein. To provide both inactive or active state GPCR models, a prediction protocol AlphaFold-MultiState (<xref rid="B13" ref-type="bibr">13</xref>) has been developed using two distinct sets of templates for the inactive and active states, respectively (<xref rid="B13" ref-type="bibr">13</xref>) based on state classifications from GPCRdb (<xref rid="B14" ref-type="bibr">14</xref>). However, the AlphaFold-MultiState models do not cover all GPCRs and were published without mention of long-term regular updates incorporating new templates (latest templates from June 2021).</p>
    <p>Ligands of GPCRs span endogenous ligands, tool compounds, drug, and agents in clinical trials. The endogenous ligands are curated by experts coordinated by the authoritative Nomenclature Committee of the International Union of Basic and Clinical Pharmacology (NC-IUPHAR, <ext-link xlink:href="https://www.guidetopharmacology.org/nomenclature.jsp" ext-link-type="uri">https://www.guidetopharmacology.org/nomenclature.jsp</ext-link>). They are provided in the Guide to Pharmacology (GtP) database (<xref rid="B15" ref-type="bibr">15</xref>) along with a classification of a receptor's principal and secondary ligand (when multiple), binding affinity (pK<sub>i</sub>) and potency (pEC<sub>50</sub>) values. The largest source of tool compounds is ChEMBL (<xref rid="B16" ref-type="bibr">16</xref>), which contains over 206 000 GPCR ligands with binding (pK<sub>i</sub>, pK<sub>d</sub>) or functional (pEC<sub>50</sub>, (pIC<sub>50</sub>)) data. Information about drugs approved by the US Food and Drug Administration is available from DrugCentral and DrugBank. Another source of consistently determined binding affinities – for psychoactive endogenous, tool and drug ligands—is the K<sub>i</sub> database from the Psychoactive Drug Screening Program (<ext-link xlink:href="https://pdsp.unc.edu/databases/kidb.php" ext-link-type="uri">https://pdsp.unc.edu/databases/kidb.php</ext-link>). Furthermore, commercial availability at vendors and physicochemical properties are provided for nearly all ligands in the PubChem database (<xref rid="B17" ref-type="bibr">17</xref>). GPCRdb has previously integrated ChEMBL ligands and PubChem data (<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B19" ref-type="bibr">19</xref>).</p>
    <p>In this article, we present an overview of all data and tool resource in our fifth major GPCRdb release, state-specific GPCR structure models (using AlphaFold2-MultiState and greatly expanded ligand resources (integrating all above ligand databases). These updates will increase GPCRdb's utility as a one-stop-shop for the GPCR community across basic research and drug discovery areas.</p>
  </sec>
  <sec sec-type="methods" id="SEC2">
    <title>METHODS</title>
    <sec id="SEC2-1">
      <title>Building state-specific GPCR structure models</title>
      <p>Due to AlphaFold's limitation regarding lack of activation state specificity, we built 844 active or inactive state AlphaFold-MultiState models for 422 GPCRs in GPCRdb. We used structural templates published up until 4 July 2022 (published AlphaFold-MultiState models were based on templates until June 2021). The use of AlphaFold-MultiState removed the need for alternative backbone templates in our previously published GPCRdb's structure modelling pipeline (<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B19" ref-type="bibr">19</xref>). All generated models are based on the full-length wildtype sequence, except for AGRV1 for which partial models were generated since this receptor comprises 6306 amino acids which exceeded our computing capabilities.</p>
    </sec>
    <sec id="SEC2-2">
      <title>Building refined GPCR structures</title>
      <p>Refined structures revert mutations to wildtype. Missing regions are filled in from an AlphaFold model based solely only the given experimental structure and fitted by superposition at junction sites.</p>
    </sec>
    <sec id="SEC2-3">
      <title>Updating of ligands and bioactivities</title>
      <p>GPCR ligands and their biological activities were imported from the ChEMBL (v. 30) (<xref rid="B16" ref-type="bibr">16</xref>), Guide to Pharmacology (v. 2022.2) (<xref rid="B15" ref-type="bibr">15</xref>) and PDSP K<sub>i</sub> databases (accessed 7 September 2022, <ext-link xlink:href="https://pdsp.unc.edu/databases/kidb.php" ext-link-type="uri">https://pdsp.unc.edu/databases/kidb.php</ext-link>), as in (<xref rid="B19" ref-type="bibr">19</xref>). Ligand physicochemical properties and commercial availability data were retrieved from the PubChem database (<xref rid="B17" ref-type="bibr">17</xref>), as in (<xref rid="B18" ref-type="bibr">18</xref>). Information about FDA approval of drugs was imported from DrugBank. To enable data integration and links to external drug (DrugBank, and DrugCentral) and ligand databases (ChEMBL, Guide to Pharmacology, and PubChem), we developed a ligand search functionality. This approach allows for searching ligands using information from different sources of information, such as ligand names, database identifiers matched via UniChem (<xref rid="B20" ref-type="bibr">20</xref>), ligand InChIKeys (calculated with RDKit, <ext-link xlink:href="http://www.rdkit.org" ext-link-type="uri">http://www.rdkit.org</ext-link>), CAS numbers via the Entrez E-utilities (<xref rid="B21" ref-type="bibr">21</xref>), UniProt accession numbers (<xref rid="B2" ref-type="bibr">2</xref>) and sequences.</p>
    </sec>
    <sec id="SEC2-4">
      <title>Building an endogenous ligand browser</title>
      <p>Endogenous ligand bioactivities and associated references were downloaded from the Guide to Pharmacology (<ext-link xlink:href="https://www.guidetopharmacology.org/download.jsp" ext-link-type="uri">https://www.guidetopharmacology.org/download.jsp</ext-link>). These data contain a ‘principal’ and ‘secondary’ classification of many, but not all, endogenous ligands that is important in many scientific studies, for example when selecting a reference ligand for physiology-biased signaling (<xref rid="B22" ref-type="bibr">22</xref>). For receptors lacking this classification and having only a single endogenous ligand we assigned the ‘principal’ category. To estimate the physiologically most important ligand for receptors with multiple unclassified ligands, we calculated a potency ranking for all endogenous ligands of each GPCR. This calculation was performed based on the mean pEC<sub>50</sub>, and if not available pK<sub>i</sub>, across studies.</p>
    </sec>
  </sec>
  <sec id="SEC3">
    <title>CURRENT DATA, ANALYSIS TOOLS AND EXPERIMENT DESIGN TOOLS</title>
    <p>Given that this is our fifth publication of a major GPCRdb release (<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B23" ref-type="bibr">23</xref>,<xref rid="B24" ref-type="bibr">24</xref>), and additional resources have published (<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B25" ref-type="bibr">25</xref>) after the latest publication (<xref rid="B19" ref-type="bibr">19</xref>), we provide an overview of the current data, analysis, data-driven experiment design, and data deposition in Figures <xref rid="F1" ref-type="fig">1</xref> and <xref rid="F2" ref-type="fig">2</xref>. Data: The updated data types span receptor sequences, isoforms (<xref rid="B26" ref-type="bibr">26</xref>), genetic variants (<xref rid="B27" ref-type="bibr">27</xref>), structures, drugs and mutations used to pinpoint ligand binding residues or (thermo-)stabilize structures (<xref rid="B28" ref-type="bibr">28</xref>). The sequences and generic residue numbers were recently expanded to cover the Class D of Ste2 fungal pheromone receptors (<xref rid="B25" ref-type="bibr">25</xref>). For refined structures, structure models, and ligands (endogenous and surrogate) we describe major updates of data or functionality in the following sections. Analysis: The analysis tools cover all of the sequence, structural and ligand/drug data spaces. Recently, we added an online GPCR structure analysis platform featuring a tool to identify functional determinants from comparative structure analysis, and trees clustering receptors by their 3D conformation (<xref rid="B14" ref-type="bibr">14</xref>). Data-driven experiment design tools: The current set of data-driven tools serve to (i) design constructs for crystallography/cryo-EM studies (<xref rid="B28" ref-type="bibr">28</xref>), (ii) identify functional determinants from comparative sequence analysis, (iii) provide mutations stabilizing inactive/active states, and mutate ligand binding sites (<xref rid="B29" ref-type="bibr">29</xref>).</p>
    <fig position="float" id="F1">
      <label>Figure 1.</label>
      <caption>
        <p>GPCR data, analysis resources and data-driven experiment tools in the GPCRdb 2023 release. The numbers to the left of each menu item are publication references with more information (including <xref rid="B30" ref-type="bibr">30–32</xref>).</p>
      </caption>
      <graphic xlink:href="gkac1013fig1" position="float"/>
    </fig>
    <fig position="float" id="F2">
      <label>Figure 2.</label>
      <caption>
        <p>Drug/ligand data, analysis, data-driven experiment tool, and data deposition in the GPCRdb 2023 release. The numbers to the left of each menu item are publication references with more information.</p>
      </caption>
      <graphic xlink:href="gkac1013fig2" position="float"/>
    </fig>
  </sec>
  <sec id="SEC4">
    <title>STRUCTURES AND MODELS</title>
    <sec id="SEC4-1">
      <title>Structures and refined structures</title>
      <p>GPCRdb makes monthly updates of GPCR structures from the Protein Data Bank (PDB) (<xref rid="B33" ref-type="bibr">33</xref>) that are complemented with manual annotation of additional information about the receptors, endogenous ligands, bound ligands, bound transducer proteins, and auxiliary proteins. This allows the <italic toggle="yes">Structures</italic> page to aid structure browsing and selection based on e.g. receptor classes, ligand, or structure properties, such as resolution. Since the last GPCRdb update publication (<xref rid="B19" ref-type="bibr">19</xref>), the number of annotated structures has increased from 488 to 788. Structures are also offered in a refined version wherein mutated residues are reverted to wildtype. Furthermore, missing regions are modelled in using AlphaFold models as swap-in templates for the missing coordinates.</p>
    </sec>
    <sec id="SEC4-2">
      <title>State-specific structure models using AlphaFold-Multistate</title>
      <p>This release contains 844 inactive or active state GPCR structure models built using AlphaFold-Multistate (exemplified in Figure <xref rid="F3" ref-type="fig">3</xref>). The models can be downloaded from the <italic toggle="yes">Structure models</italic> page with or without loop and termini segments. In a model details page, users can view the 3D structure models color-coded by the AlphaFold confidence scores. All are full length models (include loops and termini) of wildtype sequence, except for AGRV1 which had to be reduced due to its extraordinary length of 6,306 amino acids. This includes 41 new and 71 longer receptors (82 and 142 models, respectively) compared to the AlphaFold-Multistate archive, and 5 receptors (10 models) that are not available from AlphaFold Protein Structure Database (<xref rid="B12" ref-type="bibr">12</xref>) website. To provide an initial validation, we calculated root-mean-square (RMSD) values for five target structures that were published after our models were built. The validation is available in the <italic toggle="yes">Structure model validation</italic> page and yielded an average RMSD of 1.6 Å for the backbone of transmembrane domain. This supports the use of AlphaFold-Multistate for the specific modelling of activation state of GPCRs.</p>
      <fig position="float" id="F3">
        <label>Figure 3.</label>
        <caption>
          <p>Structure models of the histamine H<sub>2</sub> and serotonin 5-HT<sub>5A</sub> receptors in both the active and inactive states built with AlphaFold-Multistate.</p>
        </caption>
        <graphic xlink:href="gkac1013fig3" position="float"/>
      </fig>
      <p>The models will be updated twice a year including newly published structure templates and their determined activation state, thereby constantly improving the quality of the provided receptor models. In some cases, AlphaFold models do not represent a fully inactive or active state because there are no closely related structural templates. We will filter these models and sample more receptor conformations and explore rotamer optimization to improve docking of receptor ligands.</p>
    </sec>
  </sec>
  <sec id="SEC5">
    <title>LIGANDS</title>
    <sec id="SEC5-1">
      <title>Ligands and their coverage across GPCR targets</title>
      <p>The GPCRdb ligand resource has been updated to incorporate the most recent version of ChEMBL (<xref rid="B16" ref-type="bibr">16</xref>) and add ligands from the Guide to Pharmacology (<xref rid="B15" ref-type="bibr">15</xref>) and PDSP K<sub>i</sub> (<ext-link xlink:href="https://pdsp.unc.edu/databases/kidb.php" ext-link-type="uri">https://pdsp.unc.edu/databases/kidb.php</ext-link>) databases. It currently contains 211 320 ligands and 466 278 binding affinity or potency values (6% (&gt;20% if considering duplicates) and a 19% increase, respectively compared to GPCRdb's 2021 publication). The coverage of ligands across the receptors in the different human GPCR classes is A: 236 (75%), B1: 15 (100%), B2: 5 (15%), C: 12 (55%), F: 8 (73%) and T2: 25 (100%). Furthermore, the average number of ligands per receptor in each GPCR class is A: 612, B1: 400, C: 372, F: 90 and T2: 19.</p>
    </sec>
    <sec id="SEC5-2">
      <title>Ligand browser</title>
      <p>The receptor target selection page has added selection of receptors that are drug targets through two new columns ‘Target of an approved drug’, and ‘Target in clinical trials’, as defined in DrugBank, and DrugCentral. After selecting the receptor target, users can choose between two ligand bioactivity browsers. The ‘Compact (1 row/ligand)’ browser collates all binding or functional bioactivities of a given ligand and source database on one row by calculating minimum, average and maximum activity across studies. The ‘Extended (1 row/activity)’ browser instead lists the specific binding affinity or potency value of each study. This GPCRdb release has restructured potency and affinity data into separate tabs. It has also added fold selectivity values, along with the underlying number of experiments, allowing ligand selection based on their selectivity for the target of interest relative to all other stored GPCR targets. Both browsers also present information about vendors from which one can purchase the given ligand along with key physicochemical descriptors (<xref rid="B18" ref-type="bibr">18</xref>).</p>
    </sec>
    <sec id="SEC5-3">
      <title>Ligand info page</title>
      <p>This GPCRdb release contains a new page for individual ligands and its targets (Figure <xref rid="F4" ref-type="fig">4</xref>). This can be accessed directly by a ligand query or from the results page of the above ligand browser. The top of the ligand info page displays information about ligand structure (2D image, SMILES, InChI key), names (common, and chemical names, and aliases), physicochemical properties (molecular weight, logP and counts for hydrogen bond acceptors/donors, and rotatable bonds), molecule type (small molecule/peptide/protein, drug status and endogenous/surrogate), and database links (internal and external). For ligands that have this information, two additional boxes provide GPCR-ligand crystal/cryo-EM structure complexes and mutations affecting ligand activity. The bottom of the page shows bioactivities for the given ligand across receptor targets. The bioactivity browser allows filtering by the receptor classification, bioactivity, and source database. The information on endogenous ligands and target FDA approval status have been derived from Guide to Pharmacology (<xref rid="B15" ref-type="bibr">15</xref>) and DrugBank (<xref rid="B34" ref-type="bibr">34</xref>) databases, respectively.</p>
      <fig position="float" id="F4">
        <label>Figure 4.</label>
        <caption>
          <p>Ligand info page. The Ligands subsection of GPCRdb has been extended to 211 320 ligands and 466 278 binding affinity or potency values from the ChEMBL (<xref rid="B16" ref-type="bibr">16</xref>), Guide to Pharmacology (<xref rid="B15" ref-type="bibr">15</xref>) or PDSP K<sub>i</sub> databases (<ext-link xlink:href="https://pdsp.unc.edu/databases/kidb.php" ext-link-type="uri">https://pdsp.unc.edu/databases/kidb.php</ext-link>). The new ligand info page shows ligand structure, names, chemical properties, molecule type, drug status, and endogenous/surrogate status, and database links. When available, GPCR-ligand crystal/cryo-EM structure complexes and mutations affecting ligand activity are also shown. Bioactivities across receptor targets are shown in the browser at the bottom.</p>
        </caption>
        <graphic xlink:href="gkac1013fig4" position="float"/>
      </fig>
    </sec>
    <sec id="SEC5-4">
      <title>Endogenous ligand browser</title>
      <p>The endogenous ligand-GPCR system spans different relationships ranging (ligand:receptor) 1:1, 1:many, many:1 and many:many relationships (<xref rid="B3" ref-type="bibr">3</xref>). To facilitate browsing across either ligands or receptors, we developed an endogenous ligand browser (Figure <xref rid="F5" ref-type="fig">5</xref>). This browser contains data for 543 distinct endogenous ligands for 253 human GPCRs, and 157 mouse, rat, or guinea pig receptors. For each receptor, alternative endogenous ligands are classified as principal or secondary, as defined by the nomenclature committee of the International Union of Basic and Clinical Pharmacology (<ext-link xlink:href="https://www.guidetopharmacology.org/nomenclature.jsp" ext-link-type="uri">https://www.guidetopharmacology.org/nomenclature.jsp</ext-link>) and have an additional ranking by potency. For ligand-receptor pairs with multiple potency (pEC<sub>50</sub>) or affinity (pKi) values, the browser provides minimum, mean and maximum values, with grayscale background aiding comparison. Finally, the browser contains information about the ligand type, ligand name with a direct link to the ligand info page in GPCRdb, receptor information as family, species, IUPHAR and UniProt name and a popup showing the original references for bioactivities.</p>
      <fig position="float" id="F5">
        <label>Figure 5.</label>
        <caption>
          <p>The endogenous ligand resource offers browsing across both multiple ligand and receptors. Four sections present (i) receptors (names and classification), (ii) endogenous ligands (name with link to detailed ligand info, ligand type (small molecule, peptide, protein), classification into principal, secondary or none categories, and potency rank), (iii) bioactivities (pEC<sub>50</sub> and pK<sub>i</sub> minimum, average, and maximum values across studies) and (iv) references (publication link). All endogenous ligands and their primary/secondary classification were derived from the Guide to Pharmacology database (<xref rid="B15" ref-type="bibr">15</xref>).</p>
        </caption>
        <graphic xlink:href="gkac1013fig5" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec sec-type="data-availability" id="SEC6">
    <title>DATA AVAILABILITY</title>
    <p>GPCRdb is available at <ext-link xlink:href="https://gpcrdb.org" ext-link-type="uri">https://gpcrdb.org</ext-link> and can also be accessed via a RESTful API, which complies with the OpenAPI specification using Swagger (code examples are available at <ext-link xlink:href="https://docs.gpcrdb.org/web_services.html" ext-link-type="uri">https://docs.gpcrdb.org/web_services.html</ext-link>). The source code, the underlying data and a virtual machine configuration are all available in the repositories at <ext-link xlink:href="https://github.com/protwis/" ext-link-type="uri">https://github.com/protwis/</ext-link>.</p>
  </sec>
</body>
<back>
  <ack id="ACK1">
    <title>ACKNOWLEDGEMENTS</title>
    <p>This article is based upon work from COST Action ERNEST (CA18133), supported by COST (European Cooperation in Science and Technology, <ext-link xlink:href="http://www.cost.eu" ext-link-type="uri">www.cost.eu</ext-link>). We thank Simon Harding very much for updating the endogenous ligand download from the Guide to Pharmacology database and providing helpful communication. We thank ChemAxon (<ext-link xlink:href="http://www.chemaxon.com" ext-link-type="uri">http://www.chemaxon.com</ext-link>) for the academic license.</p>
  </ack>
  <sec id="SEC7">
    <title>FUNDING</title>
    <p>Lundbeck Foundation [R313-2019-526]; Novo Nordisk Foundation [NNF18OC0031226 to D.E.G.]; Hungarian Academy of Sciences [NAP3.0 to G.M.K.]. Funding for open access charge: Novo Nordisk Foundation [NNF18OC0031226].</p>
    <p><italic toggle="yes">Conflict of interest statement</italic>. None declared.</p>
  </sec>
  <notes id="NT1">
    <title>Notes</title>
    <p>Present address: Alibek Mamyrbekov, Trial Data Management, Novo Nordisk A/S, Vandtårnsvej 108, 2860 Søborg, Denmark.</p>
  </notes>
  <ref-list id="REF1">
    <title>REFERENCES</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gloriam</surname><given-names>D.E.</given-names></string-name>, <string-name><surname>Fredriksson</surname><given-names>R.</given-names></string-name>, <string-name><surname>Schioth</surname><given-names>H.B.</given-names></string-name></person-group><article-title>The g protein-coupled receptor subset of the rat genome</article-title>. <source>BMC Genomics</source>. <year>2007</year>; <volume>8</volume>:<fpage>338</fpage>.<pub-id pub-id-type="pmid">17892602</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><collab>UniProt Consortium</collab><article-title>UniProt: the universal protein knowledgebase in 2021</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>D480</fpage>–<lpage>D489</lpage>.<pub-id pub-id-type="pmid">33237286</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Foster</surname><given-names>S.R.</given-names></string-name>, <string-name><surname>Hauser</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Vedel</surname><given-names>L.</given-names></string-name>, <string-name><surname>Strachan</surname><given-names>R.T.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>X.P.</given-names></string-name>, <string-name><surname>Gavin</surname><given-names>A.C.</given-names></string-name>, <string-name><surname>Shah</surname><given-names>S.D.</given-names></string-name>, <string-name><surname>Nayak</surname><given-names>A.P.</given-names></string-name>, <string-name><surname>Haugaard-Kedstrom</surname><given-names>L.M.</given-names></string-name>, <string-name><surname>Penn</surname><given-names>R.B.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Discovery of human signaling systems: pairing peptides to g protein-coupled receptors</article-title>. <source>Cell</source>. <year>2019</year>; <volume>179</volume>:<fpage>895</fpage>–<lpage>908</lpage>.<pub-id pub-id-type="pmid">31675498</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hauser</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Attwood</surname><given-names>M.M.</given-names></string-name>, <string-name><surname>Rask-Andersen</surname><given-names>M.</given-names></string-name>, <string-name><surname>Schioth</surname><given-names>H.B.</given-names></string-name>, <string-name><surname>Gloriam</surname><given-names>D.E.</given-names></string-name></person-group><article-title>Trends in GPCR drug discovery: new agents, targets and indications</article-title>. <source>Nat. Rev. Drug Discov.</source><year>2017</year>; <volume>16</volume>:<fpage>829</fpage>–<lpage>842</lpage>.<pub-id pub-id-type="pmid">29075003</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wilkinson</surname><given-names>M.D.</given-names></string-name>, <string-name><surname>Dumontier</surname><given-names>M.</given-names></string-name>, <string-name><surname>Aalbersberg</surname><given-names>I.J.</given-names></string-name>, <string-name><surname>Appleton</surname><given-names>G.</given-names></string-name>, <string-name><surname>Axton</surname><given-names>M.</given-names></string-name>, <string-name><surname>Baak</surname><given-names>A.</given-names></string-name>, <string-name><surname>Blomberg</surname><given-names>N.</given-names></string-name>, <string-name><surname>Boiten</surname><given-names>J.-W.</given-names></string-name>, <string-name><surname>da Silva Santos</surname><given-names>L.B.</given-names></string-name>, <string-name><surname>Bourne</surname><given-names>P.E.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The FAIR guiding principles for scientific data management and stewardship</article-title>. <source>Sci Data</source>. <year>2016</year>; <volume>3</volume>:<fpage>160018</fpage>.<pub-id pub-id-type="pmid">26978244</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hauser</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Avet</surname><given-names>C.</given-names></string-name>, <string-name><surname>Normand</surname><given-names>C.</given-names></string-name>, <string-name><surname>Mancini</surname><given-names>A.</given-names></string-name>, <string-name><surname>Inoue</surname><given-names>A.</given-names></string-name>, <string-name><surname>Bouvier</surname><given-names>M.</given-names></string-name>, <string-name><surname>Gloriam</surname><given-names>D.E.</given-names></string-name></person-group><article-title>Common coupling map advances GPCR-G protein selectivity</article-title>. <source>Elife</source>. <year>2022</year>; <volume>11</volume>:<fpage>e74107</fpage>.<pub-id pub-id-type="pmid">35302494</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pandy-Szekeres</surname><given-names>G.</given-names></string-name>, <string-name><surname>Esguerra</surname><given-names>M.</given-names></string-name>, <string-name><surname>Hauser</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Caroli</surname><given-names>J.</given-names></string-name>, <string-name><surname>Munk</surname><given-names>C.</given-names></string-name>, <string-name><surname>Pilger</surname><given-names>S.</given-names></string-name>, <string-name><surname>Keseru</surname><given-names>G.M.</given-names></string-name>, <string-name><surname>Kooistra</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Gloriam</surname><given-names>D.E.</given-names></string-name></person-group><article-title>The g protein database, GproteinDb</article-title>. <source>Nucleic Acids Res.</source><year>2022</year>; <volume>50</volume>:<fpage>D518</fpage>–<lpage>D525</lpage>.<pub-id pub-id-type="pmid">34570219</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Caroli</surname><given-names>J.</given-names></string-name>, <string-name><surname>Pandy-Szekeres</surname><given-names>G.</given-names></string-name>, <string-name><surname>Hauser</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Keseru</surname><given-names>G.M.</given-names></string-name>, <string-name><surname>Kooistra</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Gloriam</surname><given-names>D.E.</given-names></string-name></person-group><article-title>The arrestin database</article-title>. <source>ArrestinDb</source>. <year>2022</year>; <uri xlink:href="https://arrestindb.org/">https://arrestindb.org/</uri>.</mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Caroli</surname><given-names>J.</given-names></string-name>, <string-name><surname>Mamyrbekov</surname><given-names>A.</given-names></string-name>, <string-name><surname>Harpsøe</surname><given-names>K.</given-names></string-name>, <string-name><surname>Gardizi</surname><given-names>S.</given-names></string-name>, <string-name><surname>Dörries</surname><given-names>L.</given-names></string-name>, <string-name><surname>Ghosh</surname><given-names>E.</given-names></string-name>, <string-name><surname>Hauser</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Kooistra</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Gloriam</surname><given-names>D.E.</given-names></string-name></person-group><article-title>An online biased signaling atlas</article-title>. <year>2022</year>; <comment>In Review</comment>.</mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><collab>Editorial</collab><article-title>Method of the year 2021: protein structure prediction</article-title>. <source>Nat. Methods</source>. <year>2022</year>; <volume>19</volume>:<fpage>1</fpage>.<pub-id pub-id-type="pmid">35017739</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Humphreys</surname><given-names>I.R.</given-names></string-name>, <string-name><surname>Pei</surname><given-names>J.</given-names></string-name>, <string-name><surname>Baek</surname><given-names>M.</given-names></string-name>, <string-name><surname>Krishnakumar</surname><given-names>A.</given-names></string-name>, <string-name><surname>Anishchenko</surname><given-names>I.</given-names></string-name>, <string-name><surname>Ovchinnikov</surname><given-names>S.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Ness</surname><given-names>T.J.</given-names></string-name>, <string-name><surname>Banjade</surname><given-names>S.</given-names></string-name>, <string-name><surname>Bagde</surname><given-names>S.R.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Computed structures of core eukaryotic protein complexes</article-title>. <source>Science</source>. <year>2021</year>; <volume>374</volume>:<fpage>eabm4805</fpage>.<pub-id pub-id-type="pmid">34762488</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Varadi</surname><given-names>M.</given-names></string-name>, <string-name><surname>Anyango</surname><given-names>S.</given-names></string-name>, <string-name><surname>Deshpande</surname><given-names>M.</given-names></string-name>, <string-name><surname>Nair</surname><given-names>S.</given-names></string-name>, <string-name><surname>Natassia</surname><given-names>C.</given-names></string-name>, <string-name><surname>Yordanova</surname><given-names>G.</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>D.</given-names></string-name>, <string-name><surname>Stroe</surname><given-names>O.</given-names></string-name>, <string-name><surname>Wood</surname><given-names>G.</given-names></string-name>, <string-name><surname>Laydon</surname><given-names>A.</given-names></string-name><etal>et al</etal>.</person-group><article-title>AlphaFold protein structure database: massively expanding the structural coverage of protein-sequence space with high-accuracy models</article-title>. <source>Nucleic. Acids. Res.</source><year>2021</year>; <volume>50</volume>:<fpage>D439</fpage>–<lpage>D444</lpage>.</mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Heo</surname><given-names>L.</given-names></string-name>, <string-name><surname>Feig</surname><given-names>M.</given-names></string-name></person-group><article-title>Multi-state modeling of G-protein coupled receptors at experimental accuracy</article-title>. <source>Proteins</source>. <year>2022</year>; <volume>90</volume>:<fpage>1873</fpage>–<lpage>1885</lpage>.<pub-id pub-id-type="pmid">35510704</pub-id></mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kooistra</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Munk</surname><given-names>C.</given-names></string-name>, <string-name><surname>Hauser</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Gloriam</surname><given-names>D.E.</given-names></string-name></person-group><article-title>An online GPCR structure analysis platform</article-title>. <source>Nat. Struct. Mol. Biol.</source><year>2021</year>; <volume>28</volume>:<fpage>875</fpage>–<lpage>878</lpage>.<pub-id pub-id-type="pmid">34759374</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Harding</surname><given-names>S.D.</given-names></string-name>, <string-name><surname>Armstrong</surname><given-names>J.F.</given-names></string-name>, <string-name><surname>Faccenda</surname><given-names>E.</given-names></string-name>, <string-name><surname>Southan</surname><given-names>C.</given-names></string-name>, <string-name><surname>Alexander</surname><given-names>S.P.H.</given-names></string-name>, <string-name><surname>Davenport</surname><given-names>A.P.</given-names></string-name>, <string-name><surname>Pawson</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Spedding</surname><given-names>M.</given-names></string-name>, <string-name><surname>Davies</surname><given-names>J.A.</given-names></string-name>, <string-name><surname>Nc</surname><given-names>I.</given-names></string-name></person-group><article-title>The IUPHAR/BPS guide to PHARMACOLOGY in 2022: curating pharmacology for COVID-19, malaria and antibacterials</article-title>. <source>Nucleic Acids Res.</source><year>2022</year>; <volume>50</volume>:<fpage>D1282</fpage>–<lpage>D1294</lpage>.<pub-id pub-id-type="pmid">34718737</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mendez</surname><given-names>D.</given-names></string-name>, <string-name><surname>Gaulton</surname><given-names>A.</given-names></string-name>, <string-name><surname>Bento</surname><given-names>A.P.</given-names></string-name>, <string-name><surname>Chambers</surname><given-names>J.</given-names></string-name>, <string-name><surname>De Veij</surname><given-names>M.</given-names></string-name>, <string-name><surname>Felix</surname><given-names>E.</given-names></string-name>, <string-name><surname>Magarinos</surname><given-names>M.P.</given-names></string-name>, <string-name><surname>Mosquera</surname><given-names>J.F.</given-names></string-name>, <string-name><surname>Mutowo</surname><given-names>P.</given-names></string-name>, <string-name><surname>Nowotka</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>ChEMBL: towards direct deposition of bioassay data</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>D930</fpage>–<lpage>D940</lpage>.<pub-id pub-id-type="pmid">30398643</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname><given-names>S.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>J.</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>T.</given-names></string-name>, <string-name><surname>Gindulyte</surname><given-names>A.</given-names></string-name>, <string-name><surname>He</surname><given-names>J.</given-names></string-name>, <string-name><surname>He</surname><given-names>S.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Shoemaker</surname><given-names>B.A.</given-names></string-name>, <string-name><surname>Thiessen</surname><given-names>P.A.</given-names></string-name>, <string-name><surname>Yu</surname><given-names>B.</given-names></string-name><etal>et al</etal>.</person-group><article-title>PubChem in 2021: new data content and improved web interfaces</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>D1388</fpage>–<lpage>D1395</lpage>.<pub-id pub-id-type="pmid">33151290</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pandy-Szekeres</surname><given-names>G.</given-names></string-name>, <string-name><surname>Munk</surname><given-names>C.</given-names></string-name>, <string-name><surname>Tsonkov</surname><given-names>T.M.</given-names></string-name>, <string-name><surname>Mordalski</surname><given-names>S.</given-names></string-name>, <string-name><surname>Harpsoe</surname><given-names>K.</given-names></string-name>, <string-name><surname>Hauser</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Bojarski</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Gloriam</surname><given-names>D.E.</given-names></string-name></person-group><article-title>GPCRdb in 2018: adding GPCR structure models and ligands</article-title>. <source>Nucleic Acids Res.</source><year>2018</year>; <volume>46</volume>:<fpage>D440</fpage>–<lpage>D446</lpage>.<pub-id pub-id-type="pmid">29155946</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kooistra</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Mordalski</surname><given-names>S.</given-names></string-name>, <string-name><surname>Pandy-Szekeres</surname><given-names>G.</given-names></string-name>, <string-name><surname>Esguerra</surname><given-names>M.</given-names></string-name>, <string-name><surname>Mamyrbekov</surname><given-names>A.</given-names></string-name>, <string-name><surname>Munk</surname><given-names>C.</given-names></string-name>, <string-name><surname>Keseru</surname><given-names>G.M.</given-names></string-name>, <string-name><surname>Gloriam</surname><given-names>D.E.</given-names></string-name></person-group><article-title>GPCRdb in 2021: integrating GPCR sequence, structure and function</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>D335</fpage>–<lpage>D343</lpage>.<pub-id pub-id-type="pmid">33270898</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chambers</surname><given-names>J.</given-names></string-name>, <string-name><surname>Davies</surname><given-names>M.</given-names></string-name>, <string-name><surname>Gaulton</surname><given-names>A.</given-names></string-name>, <string-name><surname>Hersey</surname><given-names>A.</given-names></string-name>, <string-name><surname>Velankar</surname><given-names>S.</given-names></string-name>, <string-name><surname>Petryszak</surname><given-names>R.</given-names></string-name>, <string-name><surname>Hastings</surname><given-names>J.</given-names></string-name>, <string-name><surname>Bellis</surname><given-names>L.</given-names></string-name>, <string-name><surname>McGlinchey</surname><given-names>S.</given-names></string-name>, <string-name><surname>Overington</surname><given-names>J.P.</given-names></string-name></person-group><article-title>UniChem: a unified chemical structure cross-referencing and identifier tracking system</article-title>. <source>J. Cheminform.</source><year>2013</year>; <volume>5</volume>:<fpage>3</fpage>.<pub-id pub-id-type="pmid">23317286</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sayers</surname><given-names>E.W.</given-names></string-name>, <string-name><surname>Beck</surname><given-names>J.</given-names></string-name>, <string-name><surname>Bolton</surname><given-names>E.E.</given-names></string-name>, <string-name><surname>Bourexis</surname><given-names>D.</given-names></string-name>, <string-name><surname>Brister</surname><given-names>J.R.</given-names></string-name>, <string-name><surname>Canese</surname><given-names>K.</given-names></string-name>, <string-name><surname>Comeau</surname><given-names>D.C.</given-names></string-name>, <string-name><surname>Funk</surname><given-names>K.</given-names></string-name>, <string-name><surname>Kim</surname><given-names>S.</given-names></string-name>, <string-name><surname>Klimke</surname><given-names>W.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Database resources of the national center for biotechnology information</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>D10</fpage>–<lpage>D17</lpage>.<pub-id pub-id-type="pmid">33095870</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kolb</surname><given-names>P.</given-names></string-name>, <string-name><surname>Kenakin</surname><given-names>T.</given-names></string-name>, <string-name><surname>Alexander</surname><given-names>S.P.H.</given-names></string-name>, <string-name><surname>Bermudez</surname><given-names>M.</given-names></string-name>, <string-name><surname>Bohn</surname><given-names>L.M.</given-names></string-name>, <string-name><surname>Breinholt</surname><given-names>C.S.</given-names></string-name>, <string-name><surname>Bouvier</surname><given-names>M.</given-names></string-name>, <string-name><surname>Hill</surname><given-names>S.J.</given-names></string-name>, <string-name><surname>Kostenis</surname><given-names>E.</given-names></string-name>, <string-name><surname>Martemyanov</surname><given-names>K.A.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Community guidelines for GPCR ligand bias: IUPHAR review 32</article-title>. <source>Br. J. Pharmacol.</source><year>2022</year>; <volume>179</volume>:<fpage>3651</fpage>–<lpage>3674</lpage>.<pub-id pub-id-type="pmid">35106752</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Isberg</surname><given-names>V.</given-names></string-name>, <string-name><surname>Mordalski</surname><given-names>S.</given-names></string-name>, <string-name><surname>Munk</surname><given-names>C.</given-names></string-name>, <string-name><surname>Rataj</surname><given-names>K.</given-names></string-name>, <string-name><surname>Harpsoe</surname><given-names>K.</given-names></string-name>, <string-name><surname>Hauser</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Vroling</surname><given-names>B.</given-names></string-name>, <string-name><surname>Bojarski</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Vriend</surname><given-names>G.</given-names></string-name>, <string-name><surname>Gloriam</surname><given-names>D.E.</given-names></string-name></person-group><article-title>GPCRdb: an information system for g protein-coupled receptors</article-title>. <source>Nucleic Acids Res.</source><year>2016</year>; <volume>44</volume>:<fpage>D356</fpage>–<lpage>D364</lpage>.<pub-id pub-id-type="pmid">26582914</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Isberg</surname><given-names>V.</given-names></string-name>, <string-name><surname>Vroling</surname><given-names>B.</given-names></string-name>, <string-name><surname>van der Kant</surname><given-names>R.</given-names></string-name>, <string-name><surname>Li</surname><given-names>K.</given-names></string-name>, <string-name><surname>Vriend</surname><given-names>G.</given-names></string-name>, <string-name><surname>Gloriam</surname><given-names>D.</given-names></string-name></person-group><article-title>GPCRDB: an information system for g protein-coupled receptors</article-title>. <source>Nucleic Acids Res.</source><year>2014</year>; <volume>42</volume>:<fpage>D422</fpage>–<lpage>D425</lpage>.<pub-id pub-id-type="pmid">24304901</pub-id></mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Velazhahan</surname><given-names>V.</given-names></string-name>, <string-name><surname>Ma</surname><given-names>N.</given-names></string-name>, <string-name><surname>Pandy-Szekeres</surname><given-names>G.</given-names></string-name>, <string-name><surname>Kooistra</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Gloriam</surname><given-names>D.E.</given-names></string-name>, <string-name><surname>Vaidehi</surname><given-names>N.</given-names></string-name>, <string-name><surname>Tate</surname><given-names>C.G.</given-names></string-name></person-group><article-title>Structure of the class d GPCR ste2 dimer coupled to two g proteins</article-title>. <source>Nature</source>. <year>2021</year>; <volume>589</volume>:<fpage>148</fpage>–<lpage>153</lpage>.<pub-id pub-id-type="pmid">33268889</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Marti-Solano</surname><given-names>M.</given-names></string-name>, <string-name><surname>Crilly</surname><given-names>S.E.</given-names></string-name>, <string-name><surname>Malinverni</surname><given-names>D.</given-names></string-name>, <string-name><surname>Munk</surname><given-names>C.</given-names></string-name>, <string-name><surname>Harris</surname><given-names>M.</given-names></string-name>, <string-name><surname>Pearce</surname><given-names>A.</given-names></string-name>, <string-name><surname>Quon</surname><given-names>T.</given-names></string-name>, <string-name><surname>Mackenzie</surname><given-names>A.E.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Peng</surname><given-names>J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Combinatorial expression of GPCR isoforms affects signalling and drug responses</article-title>. <source>Nature</source>. <year>2020</year>; <volume>587</volume>:<fpage>650</fpage>–<lpage>656</lpage>.<pub-id pub-id-type="pmid">33149304</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hauser</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Chavali</surname><given-names>S.</given-names></string-name>, <string-name><surname>Masuho</surname><given-names>I.</given-names></string-name>, <string-name><surname>Jahn</surname><given-names>L.J.</given-names></string-name>, <string-name><surname>Martemyanov</surname><given-names>K.A.</given-names></string-name>, <string-name><surname>Gloriam</surname><given-names>D.E.</given-names></string-name>, <string-name><surname>Babu</surname><given-names>M.M.</given-names></string-name></person-group><article-title>Pharmacogenomics of GPCR drug targets</article-title>. <source>Cell</source>. <year>2018</year>; <volume>172</volume>:<fpage>41</fpage>–<lpage>54</lpage>.<pub-id pub-id-type="pmid">29249361</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Munk</surname><given-names>C.</given-names></string-name>, <string-name><surname>Mutt</surname><given-names>E.</given-names></string-name>, <string-name><surname>Isberg</surname><given-names>V.</given-names></string-name>, <string-name><surname>Nikolajsen</surname><given-names>L.F.</given-names></string-name>, <string-name><surname>Bibbe</surname><given-names>J.M.</given-names></string-name>, <string-name><surname>Flock</surname><given-names>T.</given-names></string-name>, <string-name><surname>Hanson</surname><given-names>M.A.</given-names></string-name>, <string-name><surname>Stevens</surname><given-names>R.C.</given-names></string-name>, <string-name><surname>Deupi</surname><given-names>X.</given-names></string-name>, <string-name><surname>Gloriam</surname><given-names>D.E.</given-names></string-name></person-group><article-title>An online resource for GPCR structure determination and analysis</article-title>. <source>Nat. Methods</source>. <year>2019</year>; <volume>16</volume>:<fpage>151</fpage>–<lpage>162</lpage>.<pub-id pub-id-type="pmid">30664776</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Munk</surname><given-names>C.</given-names></string-name>, <string-name><surname>Harpsoe</surname><given-names>K.</given-names></string-name>, <string-name><surname>Hauser</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Isberg</surname><given-names>V.</given-names></string-name>, <string-name><surname>Gloriam</surname><given-names>D.E.</given-names></string-name></person-group><article-title>Integrating structural and mutagenesis data to elucidate GPCR ligand binding</article-title>. <source>Curr. Opin. Pharmacol.</source><year>2016</year>; <volume>30</volume>:<fpage>51</fpage>–<lpage>58</lpage>.<pub-id pub-id-type="pmid">27475047</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Isberg</surname><given-names>V.</given-names></string-name>, <string-name><surname>de Graaf</surname><given-names>C.</given-names></string-name>, <string-name><surname>Bortolato</surname><given-names>A.</given-names></string-name>, <string-name><surname>Cherezov</surname><given-names>V.</given-names></string-name>, <string-name><surname>Katritch</surname><given-names>V.</given-names></string-name>, <string-name><surname>Marshall</surname><given-names>F.H.</given-names></string-name>, <string-name><surname>Mordalski</surname><given-names>S.</given-names></string-name>, <string-name><surname>Pin</surname><given-names>J.P.</given-names></string-name>, <string-name><surname>Stevens</surname><given-names>R.C.</given-names></string-name>, <string-name><surname>Vriend</surname><given-names>G.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Generic GPCR residue numbers - aligning topology maps while minding the gaps</article-title>. <source>Trends Pharmacol. Sci.</source><year>2015</year>; <volume>36</volume>:<fpage>22</fpage>–<lpage>31</lpage>.<pub-id pub-id-type="pmid">25541108</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Munk</surname><given-names>C.</given-names></string-name>, <string-name><surname>Isberg</surname><given-names>V.</given-names></string-name>, <string-name><surname>Mordalski</surname><given-names>S.</given-names></string-name>, <string-name><surname>Harpsoe</surname><given-names>K.</given-names></string-name>, <string-name><surname>Rataj</surname><given-names>K.</given-names></string-name>, <string-name><surname>Hauser</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Kolb</surname><given-names>P.</given-names></string-name>, <string-name><surname>Bojarski</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Vriend</surname><given-names>G.</given-names></string-name>, <string-name><surname>Gloriam</surname><given-names>D.E.</given-names></string-name></person-group><article-title>GPCRdb: the g protein-coupled receptor database - an introduction</article-title>. <source>Br. J. Pharmacol.</source><year>2016</year>; <volume>173</volume>:<fpage>2195</fpage>–<lpage>2207</lpage>.<pub-id pub-id-type="pmid">27155948</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pándy-Szekeres</surname><given-names>G.</given-names></string-name>, <string-name><surname>Caroli</surname><given-names>J.</given-names></string-name>, <string-name><surname>Mamyrbekov</surname><given-names>A.</given-names></string-name>, <string-name><surname>Kermani</surname><given-names>A.A.</given-names></string-name>, <string-name><surname>Keserű</surname><given-names>G.M.</given-names></string-name>, <string-name><surname>Kooistra</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Gloriam</surname><given-names>D.E.</given-names></string-name></person-group><article-title>GPCRdb in 2023: state-specific structure models using alphafold2 and expansion of ligand resources</article-title>. <source>Nucleic Acids Res.</source><year>2022</year>; <pub-id pub-id-type="doi">10.1093/nar/gkac1013</pub-id>.</mixed-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Burley</surname><given-names>S.K.</given-names></string-name>, <string-name><surname>Bhikadiya</surname><given-names>C.</given-names></string-name>, <string-name><surname>Bi</surname><given-names>C.</given-names></string-name>, <string-name><surname>Bittrich</surname><given-names>S.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>L.</given-names></string-name>, <string-name><surname>Crichlow</surname><given-names>G.V.</given-names></string-name>, <string-name><surname>Christie</surname><given-names>C.H.</given-names></string-name>, <string-name><surname>Dalenberg</surname><given-names>K.</given-names></string-name>, <string-name><surname>Di Costanzo</surname><given-names>L.</given-names></string-name>, <string-name><surname>Duarte</surname><given-names>J.M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>RCSB protein data bank: powerful new tools for exploring 3D structures of biological macromolecules for basic and applied research and education in fundamental biology, biomedicine, biotechnology, bioengineering and energy sciences</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>D437</fpage>–<lpage>D451</lpage>.<pub-id pub-id-type="pmid">33211854</pub-id></mixed-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wishart</surname><given-names>D.S.</given-names></string-name>, <string-name><surname>Feunang</surname><given-names>Y.D.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>A.C.</given-names></string-name>, <string-name><surname>Lo</surname><given-names>E.J.</given-names></string-name>, <string-name><surname>Marcu</surname><given-names>A.</given-names></string-name>, <string-name><surname>Grant</surname><given-names>J.R.</given-names></string-name>, <string-name><surname>Sajed</surname><given-names>T.</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>D.</given-names></string-name>, <string-name><surname>Li</surname><given-names>C.</given-names></string-name>, <string-name><surname>Sayeeda</surname><given-names>Z.</given-names></string-name><etal>et al</etal>.</person-group><article-title>DrugBank 5.0: a major update to the drugbank database for 2018</article-title>. <source>Nucleic Acids Res.</source><year>2018</year>; <volume>46</volume>:<fpage>D1074</fpage>–<lpage>D1082</lpage>.<pub-id pub-id-type="pmid">29126136</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="publisher-id">nar</journal-id>
    <journal-title-group>
      <journal-title>Nucleic Acids Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0305-1048</issn>
    <issn pub-type="epub">1362-4962</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9825476</article-id>
    <article-id pub-id-type="pmid">36395823</article-id>
    <article-id pub-id-type="doi">10.1093/nar/gkac1013</article-id>
    <article-id pub-id-type="publisher-id">gkac1013</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00010</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Database Issue</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>GPCRdb in 2023: state-specific structure models using AlphaFold2 and new ligand resources</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Pándy-Szekeres</surname>
          <given-names>Gáspár</given-names>
        </name>
        <aff><institution>Department of Drug Design and Pharmacology, University of Copenhagen</institution>, Universitetsparken 2, 2100 Copenhagen, <country country="DK">Denmark</country></aff>
        <aff><institution>Medicinal Chemistry Research Group, Research Center for Natural Sciences</institution>, Budapest H-1117, <country country="HU">Hungary</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Caroli</surname>
          <given-names>Jimmy</given-names>
        </name>
        <aff><institution>Department of Drug Design and Pharmacology, University of Copenhagen</institution>, Universitetsparken 2, 2100 Copenhagen, <country country="DK">Denmark</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Mamyrbekov</surname>
          <given-names>Alibek</given-names>
        </name>
        <aff><institution>Department of Drug Design and Pharmacology, University of Copenhagen</institution>, Universitetsparken 2, 2100 Copenhagen, <country country="DK">Denmark</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Kermani</surname>
          <given-names>Ali A</given-names>
        </name>
        <aff><institution>Department of Structural Biology, St. Jude Children's Research Hospital</institution>, Memphis, TN 38105, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Keserű</surname>
          <given-names>György M</given-names>
        </name>
        <aff><institution>Medicinal Chemistry Research Group, Research Center for Natural Sciences</institution>, Budapest H-1117, <country country="HU">Hungary</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5514-6021</contrib-id>
        <name>
          <surname>Kooistra</surname>
          <given-names>Albert J</given-names>
        </name>
        <!--albert.kooistra@sund.ku.dk-->
        <aff><institution>Department of Drug Design and Pharmacology, University of Copenhagen</institution>, Universitetsparken 2, 2100 Copenhagen, <country country="DK">Denmark</country></aff>
        <xref rid="FN2" ref-type="author-notes"/>
        <xref rid="COR2" ref-type="corresp"/>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4299-7561</contrib-id>
        <name>
          <surname>Gloriam</surname>
          <given-names>David E</given-names>
        </name>
        <!--david.gloriam@sund.ku.dk-->
        <aff><institution>Department of Drug Design and Pharmacology, University of Copenhagen</institution>, Universitetsparken 2, 2100 Copenhagen, <country country="DK">Denmark</country></aff>
        <xref rid="FN2" ref-type="author-notes"/>
        <xref rid="COR1" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Tel: +45 93 56 54 49; Fax: +45 35 33 60 41; Email: <email>david.gloriam@sund.ku.dk</email></corresp>
      <corresp id="COR2">Correspondence may also be addressed to Albert J. Kooistra. Tel: +45 35 32 83 05; Email: <email>albert.kooistra@sund.ku.dk</email></corresp>
      <fn id="FN1">
        <p>The authors wish it to be known that, in their opinion, the first two authors should be regarded as Joint First Authors.</p>
      </fn>
      <fn id="FN2">
        <p>The authors wish it to be known that, in their opinion, the last two authors should be regarded as Joint Last Authors.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="collection">
      <day>06</day>
      <month>1</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2022-11-18">
      <day>18</day>
      <month>11</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>18</day>
      <month>11</month>
      <year>2022</year>
    </pub-date>
    <volume>51</volume>
    <issue>D1</issue>
    <fpage>D395</fpage>
    <lpage>D402</lpage>
    <history>
      <date date-type="accepted">
        <day>09</day>
        <month>11</month>
        <year>2022</year>
      </date>
      <date date-type="rev-recd">
        <day>15</day>
        <month>10</month>
        <year>2022</year>
      </date>
      <date date-type="received">
        <day>15</day>
        <month>9</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2022. Published by Oxford University Press on behalf of Nucleic Acids Research.</copyright-statement>
      <copyright-year>2023</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="gkac1013.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>G protein-coupled receptors (GPCRs) are physiologically abundant signaling hubs routing hundreds of extracellular signal substances and drugs into intracellular pathways. The GPCR database, GPCRdb supports &gt;5000 interdisciplinary researchers every month with reference data, analysis, visualization, experiment design and dissemination. Here, we present our fifth major GPCRdb release setting out with an overview of the many resources for receptor sequences, structures, and ligands. This includes recently published additions of class D generic residue numbers, a comparative structure analysis tool to identify functional determinants, trees clustering GPCR structures by 3D conformation, and mutations stabilizing inactive/active states. We provide new state-specific structure models of all human non-olfactory GPCRs built using AlphaFold2-MultiState. We also provide a new resource of endogenous ligands along with a larger number of surrogate ligands with bioactivity, vendor, and physiochemical descriptor data. The one-stop-shop ligand resources integrate ligands/data from the ChEMBL, Guide to Pharmacology, PDSP Ki and PubChem database. The GPCRdb is available at <ext-link xlink:href="https://gpcrdb.org" ext-link-type="uri">https://gpcrdb.org</ext-link>.</p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Lundbeck Foundation</institution>
            <institution-id institution-id-type="DOI">10.13039/501100003554</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>R313-2019-526</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Novo Nordisk Foundation</institution>
            <institution-id institution-id-type="DOI">10.13039/501100009708</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>NNF18OC0031226</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Hungarian Academy of Sciences</institution>
            <institution-id institution-id-type="DOI">10.13039/501100003825</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>NAP3.0</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="8"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>INTRODUCTION</title>
    <p>G protein-coupled receptors (GPCRs) account for 799 (<xref rid="B1" ref-type="bibr">1</xref>) out of 20 383 (<xref rid="B2" ref-type="bibr">2</xref>) (4%) human genes and transduce the responses of two-thirds (342/515) of signaling substances (<xref rid="B3" ref-type="bibr">3</xref>). Their predominant role in physiology is mirrored in medicine, as 34% of marketed drugs target GPCRs (<xref rid="B4" ref-type="bibr">4</xref>). The GPCR database, GPCRdb serves ∼5000 researchers every month with reference data, analysis, visualization, experiment design and data deposition. GPCRdb is open access and open source, and compliant with the FAIR principles (<xref rid="B5" ref-type="bibr">5</xref>). In 2022, what was previously a G protein section of GPCRdb grew into a dedicated database, GproteinDb adding, e.g. a coupling atlas integrating major datasets (<xref rid="B6" ref-type="bibr">6</xref>), structure complexes with GPCRs, and interface interactions (<xref rid="B7" ref-type="bibr">7</xref>). Also ArrestinDb (<xref rid="B8" ref-type="bibr">8</xref>) and Biased Signaling Atlas (<xref rid="B9" ref-type="bibr">9</xref>) have been much expanded and are brought forward as separate resources covering complementary aspects of signal transduction while serving dedicated research communities and use cases.</p>
    <p>GPCRdb has long provided state-of-the-art homology models from a unique multi-template pipeline. However, current advances call for a transition towards machine-learning based models taking advantage of recent breakthroughs. AlphaFold2 was, together with RoseTTA-fold, awarded the method and breakthrough of the year by <italic toggle="yes">Nature</italic> (<xref rid="B10" ref-type="bibr">10</xref>) and <italic toggle="yes">Science</italic> (<xref rid="B11" ref-type="bibr">11</xref>), respectively. While pre-generated AlphaFold2 models can be downloaded from the European Bioinformatics Institute (<xref rid="B12" ref-type="bibr">12</xref>), they have limitations of both general and GPCR-specific scope. Furthermore, AlphaFold models are provided for only one structural/functional state of each protein. To provide both inactive or active state GPCR models, a prediction protocol AlphaFold-MultiState (<xref rid="B13" ref-type="bibr">13</xref>) has been developed using two distinct sets of templates for the inactive and active states, respectively (<xref rid="B13" ref-type="bibr">13</xref>) based on state classifications from GPCRdb (<xref rid="B14" ref-type="bibr">14</xref>). However, the AlphaFold-MultiState models do not cover all GPCRs and were published without mention of long-term regular updates incorporating new templates (latest templates from June 2021).</p>
    <p>Ligands of GPCRs span endogenous ligands, tool compounds, drug, and agents in clinical trials. The endogenous ligands are curated by experts coordinated by the authoritative Nomenclature Committee of the International Union of Basic and Clinical Pharmacology (NC-IUPHAR, <ext-link xlink:href="https://www.guidetopharmacology.org/nomenclature.jsp" ext-link-type="uri">https://www.guidetopharmacology.org/nomenclature.jsp</ext-link>). They are provided in the Guide to Pharmacology (GtP) database (<xref rid="B15" ref-type="bibr">15</xref>) along with a classification of a receptor's principal and secondary ligand (when multiple), binding affinity (pK<sub>i</sub>) and potency (pEC<sub>50</sub>) values. The largest source of tool compounds is ChEMBL (<xref rid="B16" ref-type="bibr">16</xref>), which contains over 206 000 GPCR ligands with binding (pK<sub>i</sub>, pK<sub>d</sub>) or functional (pEC<sub>50</sub>, (pIC<sub>50</sub>)) data. Information about drugs approved by the US Food and Drug Administration is available from DrugCentral and DrugBank. Another source of consistently determined binding affinities – for psychoactive endogenous, tool and drug ligands—is the K<sub>i</sub> database from the Psychoactive Drug Screening Program (<ext-link xlink:href="https://pdsp.unc.edu/databases/kidb.php" ext-link-type="uri">https://pdsp.unc.edu/databases/kidb.php</ext-link>). Furthermore, commercial availability at vendors and physicochemical properties are provided for nearly all ligands in the PubChem database (<xref rid="B17" ref-type="bibr">17</xref>). GPCRdb has previously integrated ChEMBL ligands and PubChem data (<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B19" ref-type="bibr">19</xref>).</p>
    <p>In this article, we present an overview of all data and tool resource in our fifth major GPCRdb release, state-specific GPCR structure models (using AlphaFold2-MultiState and greatly expanded ligand resources (integrating all above ligand databases). These updates will increase GPCRdb's utility as a one-stop-shop for the GPCR community across basic research and drug discovery areas.</p>
  </sec>
  <sec sec-type="methods" id="SEC2">
    <title>METHODS</title>
    <sec id="SEC2-1">
      <title>Building state-specific GPCR structure models</title>
      <p>Due to AlphaFold's limitation regarding lack of activation state specificity, we built 844 active or inactive state AlphaFold-MultiState models for 422 GPCRs in GPCRdb. We used structural templates published up until 4 July 2022 (published AlphaFold-MultiState models were based on templates until June 2021). The use of AlphaFold-MultiState removed the need for alternative backbone templates in our previously published GPCRdb's structure modelling pipeline (<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B19" ref-type="bibr">19</xref>). All generated models are based on the full-length wildtype sequence, except for AGRV1 for which partial models were generated since this receptor comprises 6306 amino acids which exceeded our computing capabilities.</p>
    </sec>
    <sec id="SEC2-2">
      <title>Building refined GPCR structures</title>
      <p>Refined structures revert mutations to wildtype. Missing regions are filled in from an AlphaFold model based solely only the given experimental structure and fitted by superposition at junction sites.</p>
    </sec>
    <sec id="SEC2-3">
      <title>Updating of ligands and bioactivities</title>
      <p>GPCR ligands and their biological activities were imported from the ChEMBL (v. 30) (<xref rid="B16" ref-type="bibr">16</xref>), Guide to Pharmacology (v. 2022.2) (<xref rid="B15" ref-type="bibr">15</xref>) and PDSP K<sub>i</sub> databases (accessed 7 September 2022, <ext-link xlink:href="https://pdsp.unc.edu/databases/kidb.php" ext-link-type="uri">https://pdsp.unc.edu/databases/kidb.php</ext-link>), as in (<xref rid="B19" ref-type="bibr">19</xref>). Ligand physicochemical properties and commercial availability data were retrieved from the PubChem database (<xref rid="B17" ref-type="bibr">17</xref>), as in (<xref rid="B18" ref-type="bibr">18</xref>). Information about FDA approval of drugs was imported from DrugBank. To enable data integration and links to external drug (DrugBank, and DrugCentral) and ligand databases (ChEMBL, Guide to Pharmacology, and PubChem), we developed a ligand search functionality. This approach allows for searching ligands using information from different sources of information, such as ligand names, database identifiers matched via UniChem (<xref rid="B20" ref-type="bibr">20</xref>), ligand InChIKeys (calculated with RDKit, <ext-link xlink:href="http://www.rdkit.org" ext-link-type="uri">http://www.rdkit.org</ext-link>), CAS numbers via the Entrez E-utilities (<xref rid="B21" ref-type="bibr">21</xref>), UniProt accession numbers (<xref rid="B2" ref-type="bibr">2</xref>) and sequences.</p>
    </sec>
    <sec id="SEC2-4">
      <title>Building an endogenous ligand browser</title>
      <p>Endogenous ligand bioactivities and associated references were downloaded from the Guide to Pharmacology (<ext-link xlink:href="https://www.guidetopharmacology.org/download.jsp" ext-link-type="uri">https://www.guidetopharmacology.org/download.jsp</ext-link>). These data contain a ‘principal’ and ‘secondary’ classification of many, but not all, endogenous ligands that is important in many scientific studies, for example when selecting a reference ligand for physiology-biased signaling (<xref rid="B22" ref-type="bibr">22</xref>). For receptors lacking this classification and having only a single endogenous ligand we assigned the ‘principal’ category. To estimate the physiologically most important ligand for receptors with multiple unclassified ligands, we calculated a potency ranking for all endogenous ligands of each GPCR. This calculation was performed based on the mean pEC<sub>50</sub>, and if not available pK<sub>i</sub>, across studies.</p>
    </sec>
  </sec>
  <sec id="SEC3">
    <title>CURRENT DATA, ANALYSIS TOOLS AND EXPERIMENT DESIGN TOOLS</title>
    <p>Given that this is our fifth publication of a major GPCRdb release (<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B23" ref-type="bibr">23</xref>,<xref rid="B24" ref-type="bibr">24</xref>), and additional resources have published (<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B25" ref-type="bibr">25</xref>) after the latest publication (<xref rid="B19" ref-type="bibr">19</xref>), we provide an overview of the current data, analysis, data-driven experiment design, and data deposition in Figures <xref rid="F1" ref-type="fig">1</xref> and <xref rid="F2" ref-type="fig">2</xref>. Data: The updated data types span receptor sequences, isoforms (<xref rid="B26" ref-type="bibr">26</xref>), genetic variants (<xref rid="B27" ref-type="bibr">27</xref>), structures, drugs and mutations used to pinpoint ligand binding residues or (thermo-)stabilize structures (<xref rid="B28" ref-type="bibr">28</xref>). The sequences and generic residue numbers were recently expanded to cover the Class D of Ste2 fungal pheromone receptors (<xref rid="B25" ref-type="bibr">25</xref>). For refined structures, structure models, and ligands (endogenous and surrogate) we describe major updates of data or functionality in the following sections. Analysis: The analysis tools cover all of the sequence, structural and ligand/drug data spaces. Recently, we added an online GPCR structure analysis platform featuring a tool to identify functional determinants from comparative structure analysis, and trees clustering receptors by their 3D conformation (<xref rid="B14" ref-type="bibr">14</xref>). Data-driven experiment design tools: The current set of data-driven tools serve to (i) design constructs for crystallography/cryo-EM studies (<xref rid="B28" ref-type="bibr">28</xref>), (ii) identify functional determinants from comparative sequence analysis, (iii) provide mutations stabilizing inactive/active states, and mutate ligand binding sites (<xref rid="B29" ref-type="bibr">29</xref>).</p>
    <fig position="float" id="F1">
      <label>Figure 1.</label>
      <caption>
        <p>GPCR data, analysis resources and data-driven experiment tools in the GPCRdb 2023 release. The numbers to the left of each menu item are publication references with more information (including <xref rid="B30" ref-type="bibr">30–32</xref>).</p>
      </caption>
      <graphic xlink:href="gkac1013fig1" position="float"/>
    </fig>
    <fig position="float" id="F2">
      <label>Figure 2.</label>
      <caption>
        <p>Drug/ligand data, analysis, data-driven experiment tool, and data deposition in the GPCRdb 2023 release. The numbers to the left of each menu item are publication references with more information.</p>
      </caption>
      <graphic xlink:href="gkac1013fig2" position="float"/>
    </fig>
  </sec>
  <sec id="SEC4">
    <title>STRUCTURES AND MODELS</title>
    <sec id="SEC4-1">
      <title>Structures and refined structures</title>
      <p>GPCRdb makes monthly updates of GPCR structures from the Protein Data Bank (PDB) (<xref rid="B33" ref-type="bibr">33</xref>) that are complemented with manual annotation of additional information about the receptors, endogenous ligands, bound ligands, bound transducer proteins, and auxiliary proteins. This allows the <italic toggle="yes">Structures</italic> page to aid structure browsing and selection based on e.g. receptor classes, ligand, or structure properties, such as resolution. Since the last GPCRdb update publication (<xref rid="B19" ref-type="bibr">19</xref>), the number of annotated structures has increased from 488 to 788. Structures are also offered in a refined version wherein mutated residues are reverted to wildtype. Furthermore, missing regions are modelled in using AlphaFold models as swap-in templates for the missing coordinates.</p>
    </sec>
    <sec id="SEC4-2">
      <title>State-specific structure models using AlphaFold-Multistate</title>
      <p>This release contains 844 inactive or active state GPCR structure models built using AlphaFold-Multistate (exemplified in Figure <xref rid="F3" ref-type="fig">3</xref>). The models can be downloaded from the <italic toggle="yes">Structure models</italic> page with or without loop and termini segments. In a model details page, users can view the 3D structure models color-coded by the AlphaFold confidence scores. All are full length models (include loops and termini) of wildtype sequence, except for AGRV1 which had to be reduced due to its extraordinary length of 6,306 amino acids. This includes 41 new and 71 longer receptors (82 and 142 models, respectively) compared to the AlphaFold-Multistate archive, and 5 receptors (10 models) that are not available from AlphaFold Protein Structure Database (<xref rid="B12" ref-type="bibr">12</xref>) website. To provide an initial validation, we calculated root-mean-square (RMSD) values for five target structures that were published after our models were built. The validation is available in the <italic toggle="yes">Structure model validation</italic> page and yielded an average RMSD of 1.6 Å for the backbone of transmembrane domain. This supports the use of AlphaFold-Multistate for the specific modelling of activation state of GPCRs.</p>
      <fig position="float" id="F3">
        <label>Figure 3.</label>
        <caption>
          <p>Structure models of the histamine H<sub>2</sub> and serotonin 5-HT<sub>5A</sub> receptors in both the active and inactive states built with AlphaFold-Multistate.</p>
        </caption>
        <graphic xlink:href="gkac1013fig3" position="float"/>
      </fig>
      <p>The models will be updated twice a year including newly published structure templates and their determined activation state, thereby constantly improving the quality of the provided receptor models. In some cases, AlphaFold models do not represent a fully inactive or active state because there are no closely related structural templates. We will filter these models and sample more receptor conformations and explore rotamer optimization to improve docking of receptor ligands.</p>
    </sec>
  </sec>
  <sec id="SEC5">
    <title>LIGANDS</title>
    <sec id="SEC5-1">
      <title>Ligands and their coverage across GPCR targets</title>
      <p>The GPCRdb ligand resource has been updated to incorporate the most recent version of ChEMBL (<xref rid="B16" ref-type="bibr">16</xref>) and add ligands from the Guide to Pharmacology (<xref rid="B15" ref-type="bibr">15</xref>) and PDSP K<sub>i</sub> (<ext-link xlink:href="https://pdsp.unc.edu/databases/kidb.php" ext-link-type="uri">https://pdsp.unc.edu/databases/kidb.php</ext-link>) databases. It currently contains 211 320 ligands and 466 278 binding affinity or potency values (6% (&gt;20% if considering duplicates) and a 19% increase, respectively compared to GPCRdb's 2021 publication). The coverage of ligands across the receptors in the different human GPCR classes is A: 236 (75%), B1: 15 (100%), B2: 5 (15%), C: 12 (55%), F: 8 (73%) and T2: 25 (100%). Furthermore, the average number of ligands per receptor in each GPCR class is A: 612, B1: 400, C: 372, F: 90 and T2: 19.</p>
    </sec>
    <sec id="SEC5-2">
      <title>Ligand browser</title>
      <p>The receptor target selection page has added selection of receptors that are drug targets through two new columns ‘Target of an approved drug’, and ‘Target in clinical trials’, as defined in DrugBank, and DrugCentral. After selecting the receptor target, users can choose between two ligand bioactivity browsers. The ‘Compact (1 row/ligand)’ browser collates all binding or functional bioactivities of a given ligand and source database on one row by calculating minimum, average and maximum activity across studies. The ‘Extended (1 row/activity)’ browser instead lists the specific binding affinity or potency value of each study. This GPCRdb release has restructured potency and affinity data into separate tabs. It has also added fold selectivity values, along with the underlying number of experiments, allowing ligand selection based on their selectivity for the target of interest relative to all other stored GPCR targets. Both browsers also present information about vendors from which one can purchase the given ligand along with key physicochemical descriptors (<xref rid="B18" ref-type="bibr">18</xref>).</p>
    </sec>
    <sec id="SEC5-3">
      <title>Ligand info page</title>
      <p>This GPCRdb release contains a new page for individual ligands and its targets (Figure <xref rid="F4" ref-type="fig">4</xref>). This can be accessed directly by a ligand query or from the results page of the above ligand browser. The top of the ligand info page displays information about ligand structure (2D image, SMILES, InChI key), names (common, and chemical names, and aliases), physicochemical properties (molecular weight, logP and counts for hydrogen bond acceptors/donors, and rotatable bonds), molecule type (small molecule/peptide/protein, drug status and endogenous/surrogate), and database links (internal and external). For ligands that have this information, two additional boxes provide GPCR-ligand crystal/cryo-EM structure complexes and mutations affecting ligand activity. The bottom of the page shows bioactivities for the given ligand across receptor targets. The bioactivity browser allows filtering by the receptor classification, bioactivity, and source database. The information on endogenous ligands and target FDA approval status have been derived from Guide to Pharmacology (<xref rid="B15" ref-type="bibr">15</xref>) and DrugBank (<xref rid="B34" ref-type="bibr">34</xref>) databases, respectively.</p>
      <fig position="float" id="F4">
        <label>Figure 4.</label>
        <caption>
          <p>Ligand info page. The Ligands subsection of GPCRdb has been extended to 211 320 ligands and 466 278 binding affinity or potency values from the ChEMBL (<xref rid="B16" ref-type="bibr">16</xref>), Guide to Pharmacology (<xref rid="B15" ref-type="bibr">15</xref>) or PDSP K<sub>i</sub> databases (<ext-link xlink:href="https://pdsp.unc.edu/databases/kidb.php" ext-link-type="uri">https://pdsp.unc.edu/databases/kidb.php</ext-link>). The new ligand info page shows ligand structure, names, chemical properties, molecule type, drug status, and endogenous/surrogate status, and database links. When available, GPCR-ligand crystal/cryo-EM structure complexes and mutations affecting ligand activity are also shown. Bioactivities across receptor targets are shown in the browser at the bottom.</p>
        </caption>
        <graphic xlink:href="gkac1013fig4" position="float"/>
      </fig>
    </sec>
    <sec id="SEC5-4">
      <title>Endogenous ligand browser</title>
      <p>The endogenous ligand-GPCR system spans different relationships ranging (ligand:receptor) 1:1, 1:many, many:1 and many:many relationships (<xref rid="B3" ref-type="bibr">3</xref>). To facilitate browsing across either ligands or receptors, we developed an endogenous ligand browser (Figure <xref rid="F5" ref-type="fig">5</xref>). This browser contains data for 543 distinct endogenous ligands for 253 human GPCRs, and 157 mouse, rat, or guinea pig receptors. For each receptor, alternative endogenous ligands are classified as principal or secondary, as defined by the nomenclature committee of the International Union of Basic and Clinical Pharmacology (<ext-link xlink:href="https://www.guidetopharmacology.org/nomenclature.jsp" ext-link-type="uri">https://www.guidetopharmacology.org/nomenclature.jsp</ext-link>) and have an additional ranking by potency. For ligand-receptor pairs with multiple potency (pEC<sub>50</sub>) or affinity (pKi) values, the browser provides minimum, mean and maximum values, with grayscale background aiding comparison. Finally, the browser contains information about the ligand type, ligand name with a direct link to the ligand info page in GPCRdb, receptor information as family, species, IUPHAR and UniProt name and a popup showing the original references for bioactivities.</p>
      <fig position="float" id="F5">
        <label>Figure 5.</label>
        <caption>
          <p>The endogenous ligand resource offers browsing across both multiple ligand and receptors. Four sections present (i) receptors (names and classification), (ii) endogenous ligands (name with link to detailed ligand info, ligand type (small molecule, peptide, protein), classification into principal, secondary or none categories, and potency rank), (iii) bioactivities (pEC<sub>50</sub> and pK<sub>i</sub> minimum, average, and maximum values across studies) and (iv) references (publication link). All endogenous ligands and their primary/secondary classification were derived from the Guide to Pharmacology database (<xref rid="B15" ref-type="bibr">15</xref>).</p>
        </caption>
        <graphic xlink:href="gkac1013fig5" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec sec-type="data-availability" id="SEC6">
    <title>DATA AVAILABILITY</title>
    <p>GPCRdb is available at <ext-link xlink:href="https://gpcrdb.org" ext-link-type="uri">https://gpcrdb.org</ext-link> and can also be accessed via a RESTful API, which complies with the OpenAPI specification using Swagger (code examples are available at <ext-link xlink:href="https://docs.gpcrdb.org/web_services.html" ext-link-type="uri">https://docs.gpcrdb.org/web_services.html</ext-link>). The source code, the underlying data and a virtual machine configuration are all available in the repositories at <ext-link xlink:href="https://github.com/protwis/" ext-link-type="uri">https://github.com/protwis/</ext-link>.</p>
  </sec>
</body>
<back>
  <ack id="ACK1">
    <title>ACKNOWLEDGEMENTS</title>
    <p>This article is based upon work from COST Action ERNEST (CA18133), supported by COST (European Cooperation in Science and Technology, <ext-link xlink:href="http://www.cost.eu" ext-link-type="uri">www.cost.eu</ext-link>). We thank Simon Harding very much for updating the endogenous ligand download from the Guide to Pharmacology database and providing helpful communication. We thank ChemAxon (<ext-link xlink:href="http://www.chemaxon.com" ext-link-type="uri">http://www.chemaxon.com</ext-link>) for the academic license.</p>
  </ack>
  <sec id="SEC7">
    <title>FUNDING</title>
    <p>Lundbeck Foundation [R313-2019-526]; Novo Nordisk Foundation [NNF18OC0031226 to D.E.G.]; Hungarian Academy of Sciences [NAP3.0 to G.M.K.]. Funding for open access charge: Novo Nordisk Foundation [NNF18OC0031226].</p>
    <p><italic toggle="yes">Conflict of interest statement</italic>. None declared.</p>
  </sec>
  <notes id="NT1">
    <title>Notes</title>
    <p>Present address: Alibek Mamyrbekov, Trial Data Management, Novo Nordisk A/S, Vandtårnsvej 108, 2860 Søborg, Denmark.</p>
  </notes>
  <ref-list id="REF1">
    <title>REFERENCES</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gloriam</surname><given-names>D.E.</given-names></string-name>, <string-name><surname>Fredriksson</surname><given-names>R.</given-names></string-name>, <string-name><surname>Schioth</surname><given-names>H.B.</given-names></string-name></person-group><article-title>The g protein-coupled receptor subset of the rat genome</article-title>. <source>BMC Genomics</source>. <year>2007</year>; <volume>8</volume>:<fpage>338</fpage>.<pub-id pub-id-type="pmid">17892602</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><collab>UniProt Consortium</collab><article-title>UniProt: the universal protein knowledgebase in 2021</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>D480</fpage>–<lpage>D489</lpage>.<pub-id pub-id-type="pmid">33237286</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Foster</surname><given-names>S.R.</given-names></string-name>, <string-name><surname>Hauser</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Vedel</surname><given-names>L.</given-names></string-name>, <string-name><surname>Strachan</surname><given-names>R.T.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>X.P.</given-names></string-name>, <string-name><surname>Gavin</surname><given-names>A.C.</given-names></string-name>, <string-name><surname>Shah</surname><given-names>S.D.</given-names></string-name>, <string-name><surname>Nayak</surname><given-names>A.P.</given-names></string-name>, <string-name><surname>Haugaard-Kedstrom</surname><given-names>L.M.</given-names></string-name>, <string-name><surname>Penn</surname><given-names>R.B.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Discovery of human signaling systems: pairing peptides to g protein-coupled receptors</article-title>. <source>Cell</source>. <year>2019</year>; <volume>179</volume>:<fpage>895</fpage>–<lpage>908</lpage>.<pub-id pub-id-type="pmid">31675498</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hauser</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Attwood</surname><given-names>M.M.</given-names></string-name>, <string-name><surname>Rask-Andersen</surname><given-names>M.</given-names></string-name>, <string-name><surname>Schioth</surname><given-names>H.B.</given-names></string-name>, <string-name><surname>Gloriam</surname><given-names>D.E.</given-names></string-name></person-group><article-title>Trends in GPCR drug discovery: new agents, targets and indications</article-title>. <source>Nat. Rev. Drug Discov.</source><year>2017</year>; <volume>16</volume>:<fpage>829</fpage>–<lpage>842</lpage>.<pub-id pub-id-type="pmid">29075003</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wilkinson</surname><given-names>M.D.</given-names></string-name>, <string-name><surname>Dumontier</surname><given-names>M.</given-names></string-name>, <string-name><surname>Aalbersberg</surname><given-names>I.J.</given-names></string-name>, <string-name><surname>Appleton</surname><given-names>G.</given-names></string-name>, <string-name><surname>Axton</surname><given-names>M.</given-names></string-name>, <string-name><surname>Baak</surname><given-names>A.</given-names></string-name>, <string-name><surname>Blomberg</surname><given-names>N.</given-names></string-name>, <string-name><surname>Boiten</surname><given-names>J.-W.</given-names></string-name>, <string-name><surname>da Silva Santos</surname><given-names>L.B.</given-names></string-name>, <string-name><surname>Bourne</surname><given-names>P.E.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The FAIR guiding principles for scientific data management and stewardship</article-title>. <source>Sci Data</source>. <year>2016</year>; <volume>3</volume>:<fpage>160018</fpage>.<pub-id pub-id-type="pmid">26978244</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hauser</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Avet</surname><given-names>C.</given-names></string-name>, <string-name><surname>Normand</surname><given-names>C.</given-names></string-name>, <string-name><surname>Mancini</surname><given-names>A.</given-names></string-name>, <string-name><surname>Inoue</surname><given-names>A.</given-names></string-name>, <string-name><surname>Bouvier</surname><given-names>M.</given-names></string-name>, <string-name><surname>Gloriam</surname><given-names>D.E.</given-names></string-name></person-group><article-title>Common coupling map advances GPCR-G protein selectivity</article-title>. <source>Elife</source>. <year>2022</year>; <volume>11</volume>:<fpage>e74107</fpage>.<pub-id pub-id-type="pmid">35302494</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pandy-Szekeres</surname><given-names>G.</given-names></string-name>, <string-name><surname>Esguerra</surname><given-names>M.</given-names></string-name>, <string-name><surname>Hauser</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Caroli</surname><given-names>J.</given-names></string-name>, <string-name><surname>Munk</surname><given-names>C.</given-names></string-name>, <string-name><surname>Pilger</surname><given-names>S.</given-names></string-name>, <string-name><surname>Keseru</surname><given-names>G.M.</given-names></string-name>, <string-name><surname>Kooistra</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Gloriam</surname><given-names>D.E.</given-names></string-name></person-group><article-title>The g protein database, GproteinDb</article-title>. <source>Nucleic Acids Res.</source><year>2022</year>; <volume>50</volume>:<fpage>D518</fpage>–<lpage>D525</lpage>.<pub-id pub-id-type="pmid">34570219</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Caroli</surname><given-names>J.</given-names></string-name>, <string-name><surname>Pandy-Szekeres</surname><given-names>G.</given-names></string-name>, <string-name><surname>Hauser</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Keseru</surname><given-names>G.M.</given-names></string-name>, <string-name><surname>Kooistra</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Gloriam</surname><given-names>D.E.</given-names></string-name></person-group><article-title>The arrestin database</article-title>. <source>ArrestinDb</source>. <year>2022</year>; <uri xlink:href="https://arrestindb.org/">https://arrestindb.org/</uri>.</mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Caroli</surname><given-names>J.</given-names></string-name>, <string-name><surname>Mamyrbekov</surname><given-names>A.</given-names></string-name>, <string-name><surname>Harpsøe</surname><given-names>K.</given-names></string-name>, <string-name><surname>Gardizi</surname><given-names>S.</given-names></string-name>, <string-name><surname>Dörries</surname><given-names>L.</given-names></string-name>, <string-name><surname>Ghosh</surname><given-names>E.</given-names></string-name>, <string-name><surname>Hauser</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Kooistra</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Gloriam</surname><given-names>D.E.</given-names></string-name></person-group><article-title>An online biased signaling atlas</article-title>. <year>2022</year>; <comment>In Review</comment>.</mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><collab>Editorial</collab><article-title>Method of the year 2021: protein structure prediction</article-title>. <source>Nat. Methods</source>. <year>2022</year>; <volume>19</volume>:<fpage>1</fpage>.<pub-id pub-id-type="pmid">35017739</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Humphreys</surname><given-names>I.R.</given-names></string-name>, <string-name><surname>Pei</surname><given-names>J.</given-names></string-name>, <string-name><surname>Baek</surname><given-names>M.</given-names></string-name>, <string-name><surname>Krishnakumar</surname><given-names>A.</given-names></string-name>, <string-name><surname>Anishchenko</surname><given-names>I.</given-names></string-name>, <string-name><surname>Ovchinnikov</surname><given-names>S.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Ness</surname><given-names>T.J.</given-names></string-name>, <string-name><surname>Banjade</surname><given-names>S.</given-names></string-name>, <string-name><surname>Bagde</surname><given-names>S.R.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Computed structures of core eukaryotic protein complexes</article-title>. <source>Science</source>. <year>2021</year>; <volume>374</volume>:<fpage>eabm4805</fpage>.<pub-id pub-id-type="pmid">34762488</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Varadi</surname><given-names>M.</given-names></string-name>, <string-name><surname>Anyango</surname><given-names>S.</given-names></string-name>, <string-name><surname>Deshpande</surname><given-names>M.</given-names></string-name>, <string-name><surname>Nair</surname><given-names>S.</given-names></string-name>, <string-name><surname>Natassia</surname><given-names>C.</given-names></string-name>, <string-name><surname>Yordanova</surname><given-names>G.</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>D.</given-names></string-name>, <string-name><surname>Stroe</surname><given-names>O.</given-names></string-name>, <string-name><surname>Wood</surname><given-names>G.</given-names></string-name>, <string-name><surname>Laydon</surname><given-names>A.</given-names></string-name><etal>et al</etal>.</person-group><article-title>AlphaFold protein structure database: massively expanding the structural coverage of protein-sequence space with high-accuracy models</article-title>. <source>Nucleic. Acids. Res.</source><year>2021</year>; <volume>50</volume>:<fpage>D439</fpage>–<lpage>D444</lpage>.</mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Heo</surname><given-names>L.</given-names></string-name>, <string-name><surname>Feig</surname><given-names>M.</given-names></string-name></person-group><article-title>Multi-state modeling of G-protein coupled receptors at experimental accuracy</article-title>. <source>Proteins</source>. <year>2022</year>; <volume>90</volume>:<fpage>1873</fpage>–<lpage>1885</lpage>.<pub-id pub-id-type="pmid">35510704</pub-id></mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kooistra</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Munk</surname><given-names>C.</given-names></string-name>, <string-name><surname>Hauser</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Gloriam</surname><given-names>D.E.</given-names></string-name></person-group><article-title>An online GPCR structure analysis platform</article-title>. <source>Nat. Struct. Mol. Biol.</source><year>2021</year>; <volume>28</volume>:<fpage>875</fpage>–<lpage>878</lpage>.<pub-id pub-id-type="pmid">34759374</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Harding</surname><given-names>S.D.</given-names></string-name>, <string-name><surname>Armstrong</surname><given-names>J.F.</given-names></string-name>, <string-name><surname>Faccenda</surname><given-names>E.</given-names></string-name>, <string-name><surname>Southan</surname><given-names>C.</given-names></string-name>, <string-name><surname>Alexander</surname><given-names>S.P.H.</given-names></string-name>, <string-name><surname>Davenport</surname><given-names>A.P.</given-names></string-name>, <string-name><surname>Pawson</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Spedding</surname><given-names>M.</given-names></string-name>, <string-name><surname>Davies</surname><given-names>J.A.</given-names></string-name>, <string-name><surname>Nc</surname><given-names>I.</given-names></string-name></person-group><article-title>The IUPHAR/BPS guide to PHARMACOLOGY in 2022: curating pharmacology for COVID-19, malaria and antibacterials</article-title>. <source>Nucleic Acids Res.</source><year>2022</year>; <volume>50</volume>:<fpage>D1282</fpage>–<lpage>D1294</lpage>.<pub-id pub-id-type="pmid">34718737</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mendez</surname><given-names>D.</given-names></string-name>, <string-name><surname>Gaulton</surname><given-names>A.</given-names></string-name>, <string-name><surname>Bento</surname><given-names>A.P.</given-names></string-name>, <string-name><surname>Chambers</surname><given-names>J.</given-names></string-name>, <string-name><surname>De Veij</surname><given-names>M.</given-names></string-name>, <string-name><surname>Felix</surname><given-names>E.</given-names></string-name>, <string-name><surname>Magarinos</surname><given-names>M.P.</given-names></string-name>, <string-name><surname>Mosquera</surname><given-names>J.F.</given-names></string-name>, <string-name><surname>Mutowo</surname><given-names>P.</given-names></string-name>, <string-name><surname>Nowotka</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>ChEMBL: towards direct deposition of bioassay data</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>D930</fpage>–<lpage>D940</lpage>.<pub-id pub-id-type="pmid">30398643</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname><given-names>S.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>J.</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>T.</given-names></string-name>, <string-name><surname>Gindulyte</surname><given-names>A.</given-names></string-name>, <string-name><surname>He</surname><given-names>J.</given-names></string-name>, <string-name><surname>He</surname><given-names>S.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Shoemaker</surname><given-names>B.A.</given-names></string-name>, <string-name><surname>Thiessen</surname><given-names>P.A.</given-names></string-name>, <string-name><surname>Yu</surname><given-names>B.</given-names></string-name><etal>et al</etal>.</person-group><article-title>PubChem in 2021: new data content and improved web interfaces</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>D1388</fpage>–<lpage>D1395</lpage>.<pub-id pub-id-type="pmid">33151290</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pandy-Szekeres</surname><given-names>G.</given-names></string-name>, <string-name><surname>Munk</surname><given-names>C.</given-names></string-name>, <string-name><surname>Tsonkov</surname><given-names>T.M.</given-names></string-name>, <string-name><surname>Mordalski</surname><given-names>S.</given-names></string-name>, <string-name><surname>Harpsoe</surname><given-names>K.</given-names></string-name>, <string-name><surname>Hauser</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Bojarski</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Gloriam</surname><given-names>D.E.</given-names></string-name></person-group><article-title>GPCRdb in 2018: adding GPCR structure models and ligands</article-title>. <source>Nucleic Acids Res.</source><year>2018</year>; <volume>46</volume>:<fpage>D440</fpage>–<lpage>D446</lpage>.<pub-id pub-id-type="pmid">29155946</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kooistra</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Mordalski</surname><given-names>S.</given-names></string-name>, <string-name><surname>Pandy-Szekeres</surname><given-names>G.</given-names></string-name>, <string-name><surname>Esguerra</surname><given-names>M.</given-names></string-name>, <string-name><surname>Mamyrbekov</surname><given-names>A.</given-names></string-name>, <string-name><surname>Munk</surname><given-names>C.</given-names></string-name>, <string-name><surname>Keseru</surname><given-names>G.M.</given-names></string-name>, <string-name><surname>Gloriam</surname><given-names>D.E.</given-names></string-name></person-group><article-title>GPCRdb in 2021: integrating GPCR sequence, structure and function</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>D335</fpage>–<lpage>D343</lpage>.<pub-id pub-id-type="pmid">33270898</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chambers</surname><given-names>J.</given-names></string-name>, <string-name><surname>Davies</surname><given-names>M.</given-names></string-name>, <string-name><surname>Gaulton</surname><given-names>A.</given-names></string-name>, <string-name><surname>Hersey</surname><given-names>A.</given-names></string-name>, <string-name><surname>Velankar</surname><given-names>S.</given-names></string-name>, <string-name><surname>Petryszak</surname><given-names>R.</given-names></string-name>, <string-name><surname>Hastings</surname><given-names>J.</given-names></string-name>, <string-name><surname>Bellis</surname><given-names>L.</given-names></string-name>, <string-name><surname>McGlinchey</surname><given-names>S.</given-names></string-name>, <string-name><surname>Overington</surname><given-names>J.P.</given-names></string-name></person-group><article-title>UniChem: a unified chemical structure cross-referencing and identifier tracking system</article-title>. <source>J. Cheminform.</source><year>2013</year>; <volume>5</volume>:<fpage>3</fpage>.<pub-id pub-id-type="pmid">23317286</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sayers</surname><given-names>E.W.</given-names></string-name>, <string-name><surname>Beck</surname><given-names>J.</given-names></string-name>, <string-name><surname>Bolton</surname><given-names>E.E.</given-names></string-name>, <string-name><surname>Bourexis</surname><given-names>D.</given-names></string-name>, <string-name><surname>Brister</surname><given-names>J.R.</given-names></string-name>, <string-name><surname>Canese</surname><given-names>K.</given-names></string-name>, <string-name><surname>Comeau</surname><given-names>D.C.</given-names></string-name>, <string-name><surname>Funk</surname><given-names>K.</given-names></string-name>, <string-name><surname>Kim</surname><given-names>S.</given-names></string-name>, <string-name><surname>Klimke</surname><given-names>W.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Database resources of the national center for biotechnology information</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>D10</fpage>–<lpage>D17</lpage>.<pub-id pub-id-type="pmid">33095870</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kolb</surname><given-names>P.</given-names></string-name>, <string-name><surname>Kenakin</surname><given-names>T.</given-names></string-name>, <string-name><surname>Alexander</surname><given-names>S.P.H.</given-names></string-name>, <string-name><surname>Bermudez</surname><given-names>M.</given-names></string-name>, <string-name><surname>Bohn</surname><given-names>L.M.</given-names></string-name>, <string-name><surname>Breinholt</surname><given-names>C.S.</given-names></string-name>, <string-name><surname>Bouvier</surname><given-names>M.</given-names></string-name>, <string-name><surname>Hill</surname><given-names>S.J.</given-names></string-name>, <string-name><surname>Kostenis</surname><given-names>E.</given-names></string-name>, <string-name><surname>Martemyanov</surname><given-names>K.A.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Community guidelines for GPCR ligand bias: IUPHAR review 32</article-title>. <source>Br. J. Pharmacol.</source><year>2022</year>; <volume>179</volume>:<fpage>3651</fpage>–<lpage>3674</lpage>.<pub-id pub-id-type="pmid">35106752</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Isberg</surname><given-names>V.</given-names></string-name>, <string-name><surname>Mordalski</surname><given-names>S.</given-names></string-name>, <string-name><surname>Munk</surname><given-names>C.</given-names></string-name>, <string-name><surname>Rataj</surname><given-names>K.</given-names></string-name>, <string-name><surname>Harpsoe</surname><given-names>K.</given-names></string-name>, <string-name><surname>Hauser</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Vroling</surname><given-names>B.</given-names></string-name>, <string-name><surname>Bojarski</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Vriend</surname><given-names>G.</given-names></string-name>, <string-name><surname>Gloriam</surname><given-names>D.E.</given-names></string-name></person-group><article-title>GPCRdb: an information system for g protein-coupled receptors</article-title>. <source>Nucleic Acids Res.</source><year>2016</year>; <volume>44</volume>:<fpage>D356</fpage>–<lpage>D364</lpage>.<pub-id pub-id-type="pmid">26582914</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Isberg</surname><given-names>V.</given-names></string-name>, <string-name><surname>Vroling</surname><given-names>B.</given-names></string-name>, <string-name><surname>van der Kant</surname><given-names>R.</given-names></string-name>, <string-name><surname>Li</surname><given-names>K.</given-names></string-name>, <string-name><surname>Vriend</surname><given-names>G.</given-names></string-name>, <string-name><surname>Gloriam</surname><given-names>D.</given-names></string-name></person-group><article-title>GPCRDB: an information system for g protein-coupled receptors</article-title>. <source>Nucleic Acids Res.</source><year>2014</year>; <volume>42</volume>:<fpage>D422</fpage>–<lpage>D425</lpage>.<pub-id pub-id-type="pmid">24304901</pub-id></mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Velazhahan</surname><given-names>V.</given-names></string-name>, <string-name><surname>Ma</surname><given-names>N.</given-names></string-name>, <string-name><surname>Pandy-Szekeres</surname><given-names>G.</given-names></string-name>, <string-name><surname>Kooistra</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Gloriam</surname><given-names>D.E.</given-names></string-name>, <string-name><surname>Vaidehi</surname><given-names>N.</given-names></string-name>, <string-name><surname>Tate</surname><given-names>C.G.</given-names></string-name></person-group><article-title>Structure of the class d GPCR ste2 dimer coupled to two g proteins</article-title>. <source>Nature</source>. <year>2021</year>; <volume>589</volume>:<fpage>148</fpage>–<lpage>153</lpage>.<pub-id pub-id-type="pmid">33268889</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Marti-Solano</surname><given-names>M.</given-names></string-name>, <string-name><surname>Crilly</surname><given-names>S.E.</given-names></string-name>, <string-name><surname>Malinverni</surname><given-names>D.</given-names></string-name>, <string-name><surname>Munk</surname><given-names>C.</given-names></string-name>, <string-name><surname>Harris</surname><given-names>M.</given-names></string-name>, <string-name><surname>Pearce</surname><given-names>A.</given-names></string-name>, <string-name><surname>Quon</surname><given-names>T.</given-names></string-name>, <string-name><surname>Mackenzie</surname><given-names>A.E.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Peng</surname><given-names>J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Combinatorial expression of GPCR isoforms affects signalling and drug responses</article-title>. <source>Nature</source>. <year>2020</year>; <volume>587</volume>:<fpage>650</fpage>–<lpage>656</lpage>.<pub-id pub-id-type="pmid">33149304</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hauser</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Chavali</surname><given-names>S.</given-names></string-name>, <string-name><surname>Masuho</surname><given-names>I.</given-names></string-name>, <string-name><surname>Jahn</surname><given-names>L.J.</given-names></string-name>, <string-name><surname>Martemyanov</surname><given-names>K.A.</given-names></string-name>, <string-name><surname>Gloriam</surname><given-names>D.E.</given-names></string-name>, <string-name><surname>Babu</surname><given-names>M.M.</given-names></string-name></person-group><article-title>Pharmacogenomics of GPCR drug targets</article-title>. <source>Cell</source>. <year>2018</year>; <volume>172</volume>:<fpage>41</fpage>–<lpage>54</lpage>.<pub-id pub-id-type="pmid">29249361</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Munk</surname><given-names>C.</given-names></string-name>, <string-name><surname>Mutt</surname><given-names>E.</given-names></string-name>, <string-name><surname>Isberg</surname><given-names>V.</given-names></string-name>, <string-name><surname>Nikolajsen</surname><given-names>L.F.</given-names></string-name>, <string-name><surname>Bibbe</surname><given-names>J.M.</given-names></string-name>, <string-name><surname>Flock</surname><given-names>T.</given-names></string-name>, <string-name><surname>Hanson</surname><given-names>M.A.</given-names></string-name>, <string-name><surname>Stevens</surname><given-names>R.C.</given-names></string-name>, <string-name><surname>Deupi</surname><given-names>X.</given-names></string-name>, <string-name><surname>Gloriam</surname><given-names>D.E.</given-names></string-name></person-group><article-title>An online resource for GPCR structure determination and analysis</article-title>. <source>Nat. Methods</source>. <year>2019</year>; <volume>16</volume>:<fpage>151</fpage>–<lpage>162</lpage>.<pub-id pub-id-type="pmid">30664776</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Munk</surname><given-names>C.</given-names></string-name>, <string-name><surname>Harpsoe</surname><given-names>K.</given-names></string-name>, <string-name><surname>Hauser</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Isberg</surname><given-names>V.</given-names></string-name>, <string-name><surname>Gloriam</surname><given-names>D.E.</given-names></string-name></person-group><article-title>Integrating structural and mutagenesis data to elucidate GPCR ligand binding</article-title>. <source>Curr. Opin. Pharmacol.</source><year>2016</year>; <volume>30</volume>:<fpage>51</fpage>–<lpage>58</lpage>.<pub-id pub-id-type="pmid">27475047</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Isberg</surname><given-names>V.</given-names></string-name>, <string-name><surname>de Graaf</surname><given-names>C.</given-names></string-name>, <string-name><surname>Bortolato</surname><given-names>A.</given-names></string-name>, <string-name><surname>Cherezov</surname><given-names>V.</given-names></string-name>, <string-name><surname>Katritch</surname><given-names>V.</given-names></string-name>, <string-name><surname>Marshall</surname><given-names>F.H.</given-names></string-name>, <string-name><surname>Mordalski</surname><given-names>S.</given-names></string-name>, <string-name><surname>Pin</surname><given-names>J.P.</given-names></string-name>, <string-name><surname>Stevens</surname><given-names>R.C.</given-names></string-name>, <string-name><surname>Vriend</surname><given-names>G.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Generic GPCR residue numbers - aligning topology maps while minding the gaps</article-title>. <source>Trends Pharmacol. Sci.</source><year>2015</year>; <volume>36</volume>:<fpage>22</fpage>–<lpage>31</lpage>.<pub-id pub-id-type="pmid">25541108</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Munk</surname><given-names>C.</given-names></string-name>, <string-name><surname>Isberg</surname><given-names>V.</given-names></string-name>, <string-name><surname>Mordalski</surname><given-names>S.</given-names></string-name>, <string-name><surname>Harpsoe</surname><given-names>K.</given-names></string-name>, <string-name><surname>Rataj</surname><given-names>K.</given-names></string-name>, <string-name><surname>Hauser</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Kolb</surname><given-names>P.</given-names></string-name>, <string-name><surname>Bojarski</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Vriend</surname><given-names>G.</given-names></string-name>, <string-name><surname>Gloriam</surname><given-names>D.E.</given-names></string-name></person-group><article-title>GPCRdb: the g protein-coupled receptor database - an introduction</article-title>. <source>Br. J. Pharmacol.</source><year>2016</year>; <volume>173</volume>:<fpage>2195</fpage>–<lpage>2207</lpage>.<pub-id pub-id-type="pmid">27155948</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pándy-Szekeres</surname><given-names>G.</given-names></string-name>, <string-name><surname>Caroli</surname><given-names>J.</given-names></string-name>, <string-name><surname>Mamyrbekov</surname><given-names>A.</given-names></string-name>, <string-name><surname>Kermani</surname><given-names>A.A.</given-names></string-name>, <string-name><surname>Keserű</surname><given-names>G.M.</given-names></string-name>, <string-name><surname>Kooistra</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Gloriam</surname><given-names>D.E.</given-names></string-name></person-group><article-title>GPCRdb in 2023: state-specific structure models using alphafold2 and expansion of ligand resources</article-title>. <source>Nucleic Acids Res.</source><year>2022</year>; <pub-id pub-id-type="doi">10.1093/nar/gkac1013</pub-id>.</mixed-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Burley</surname><given-names>S.K.</given-names></string-name>, <string-name><surname>Bhikadiya</surname><given-names>C.</given-names></string-name>, <string-name><surname>Bi</surname><given-names>C.</given-names></string-name>, <string-name><surname>Bittrich</surname><given-names>S.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>L.</given-names></string-name>, <string-name><surname>Crichlow</surname><given-names>G.V.</given-names></string-name>, <string-name><surname>Christie</surname><given-names>C.H.</given-names></string-name>, <string-name><surname>Dalenberg</surname><given-names>K.</given-names></string-name>, <string-name><surname>Di Costanzo</surname><given-names>L.</given-names></string-name>, <string-name><surname>Duarte</surname><given-names>J.M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>RCSB protein data bank: powerful new tools for exploring 3D structures of biological macromolecules for basic and applied research and education in fundamental biology, biomedicine, biotechnology, bioengineering and energy sciences</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>D437</fpage>–<lpage>D451</lpage>.<pub-id pub-id-type="pmid">33211854</pub-id></mixed-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wishart</surname><given-names>D.S.</given-names></string-name>, <string-name><surname>Feunang</surname><given-names>Y.D.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>A.C.</given-names></string-name>, <string-name><surname>Lo</surname><given-names>E.J.</given-names></string-name>, <string-name><surname>Marcu</surname><given-names>A.</given-names></string-name>, <string-name><surname>Grant</surname><given-names>J.R.</given-names></string-name>, <string-name><surname>Sajed</surname><given-names>T.</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>D.</given-names></string-name>, <string-name><surname>Li</surname><given-names>C.</given-names></string-name>, <string-name><surname>Sayeeda</surname><given-names>Z.</given-names></string-name><etal>et al</etal>.</person-group><article-title>DrugBank 5.0: a major update to the drugbank database for 2018</article-title>. <source>Nucleic Acids Res.</source><year>2018</year>; <volume>46</volume>:<fpage>D1074</fpage>–<lpage>D1082</lpage>.<pub-id pub-id-type="pmid">29126136</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
